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Abstract 
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a complex, life-threatening 
genetic skin disorder with painful complications.  Currently, there is no cure, but there 
have been recent developments in both the basic biological research aspects and the 
translational therapies which make effectively treating this disease more likely in the near 
future.  These advances include the use of stem cells and gene editing as well as new 
insights into the molecular mechanisms for certain aspects of RDEB pathology.   The 
overall goals of our lab are to better define and characterize RDEB pathology, develop 
novel approaches for treating RDEB, and to improve upon the ways in which we analyze 
and understand the outcomes of those therapies.  These goals are inherently dependent 
upon a comprehensive understanding of how type VII collagen is regulated, both during 
the normal wound healing process and over the course of therapeutic intervention. 
 To that aim, we set out to understand two aspects of regulation of type VII 
collagen that were poorly understood: one focused on the nature of type VII collagen 
regulation during wound healing and the other focused on type VII collagen regulation 
during the hematopoietic stem cell transplantation process.  We identified a particular 
micro RNA, miR-29, which regulates COL7A1 transcriptionally and post-
transcriptionally.  We also demonstrated that fludarabine, a key component of the 
hematopoietic cell transplantation (HCT) preparative regimen, modulates type VII 
collagen expression during hematopoietic stem cell transplantation.  Our studies have 
identified a novel mechanism of regulation for type VII collagen that will hopefully give 
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valuable insight into how to treat RDEB, ameliorate RDEB pathology, and properly 
evaluate clinical outcomes in patients that have receive HCT to treat RDEB. 
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Chapter 1: Introduction 
Collagen VII, basic biology and implications for therapeutic approaches for treating 
RDEB 
 Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare genetic skin 
disorder characterized by chronic skin blistering, scarring, and abnormal wound healing.  
The underlying genetic defects that cause RDEB are loss-of-function mutations in the 
gene COL7A1, which encodes the essential extracellular matrix protein type VII collagen 
(C7).  C7 is assembled as a homo-trimer and deposited at the dermal-epidermal junction 
(DEJ) as a mature anchoring fibril.  Here it functions to stabilize the junction and 
maintain structural support joining the dermis and the epidermis. C7 is typically 
synthesized by keratinocytes and fibroblasts, the two major cell types of the epidermis 
and dermis, respectively. There are multiple facets of regulation from transcription, 
translation, protein processing that control how type VII collagen is made and eventually 
deposited as a fully matured anchoring fibril. Many of the steps of regulation are tightly 
linked to cellular processes involved in inflammation and wound healing, as well as cell-
type specific responses to signals associated with inflammation and wound healing. 
RDEB pathology reflects not only the direct consequences of loss of C7 function but the 
cascade of dysregulated wound healing and cellular responses to inflammation 
surrounding the loss of C7 as well. Understanding how type VII collagen is regulated is 
crucial in developing cellular and genetic approaches to treating RDEB as well as 
developing proper analytical tests to evaluate how effective clinical interventions are. 
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COL7A1 at the genetic level 
The COL7A1 locus is located on Chromosome 3 at the 3p.21 region.  The gene itself is 
roughly 32KB in length, and contains 118 exons, one of the highest numbers of exons for 
a human transcript (Christiano et al. 1994b).  Causative mutations for Recessive 
Dystrophic Epidermolysis Bullosa are distributed among the entire coding region and 
include missense mutations, nonsense mutations as well as mutations that interfere with 
splicing.  The most common consequence of causative mutations in RDEB are pre-
termination codons, which lead to the production of dysfunctional or short, truncated 
versions of type VII collagen.  There has been some disagreement as to whether 
differences in these truncated versions have any influence on both the severity of RDEB 
or the incidence of squamous cell carcinoma in RDEB, but no definitive outcome for 
either has been established (Ortiz-Urda et al. 2005; Pourreyron et al. 2007). However, the 
mutations are not equally distributed, with clustering of mutations existing near exon 73 
(Varki et al. 2006).  Furthermore, certain mutations in the COL7A1 locus lead to another 
form of epidermolysis bullosa known as Dominant Dystrophic Epidermolysis Bullosa 
rather than RDEB, where mutations that interfere with type VII collagen assembly 
disrupt the proper formation of the C7 homotrimer. The genetic inheritance of RDEB 
typically includes a pattern of compound heterozygosity (Christiano et al. 1994a; Dang 
and Murrell 2008; Dunnill et al. 1996). 
 Much of the studies investigating how COL7A1 is regulated have focused on 
transcriptional control, specifically the transcription factors that regulate and bind the 
COL7A1 promoter. The COL7A1 promoter contains a core region of roughly 500 bp that 
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contains the majority of known transcriptional response elements (TRE) for COL7A1.  
COL7A1 is different from other genes in that it lacks a canonical TATA box; it contains 
an SP1 response element responsible for its basal level transcription (Vindevoghel et al. 
1997).  Beyond the initial SP1 response element, another SP1 element exists closer to the 
transcriptional start site which was identified serendipitously via characterization of a 
mutation in one of the alleles in the promoter that led to RDEB in a patient (Gardella et 
al. 2000).  These sites exist at -512 and -96 bp with respect to the transcriptional start site 
(TSS) (Figure 1). 
 Beyond basal level transcription, multiple transcription factors regulate COL7A1 
expression in a cell-specific manner.  Specifically, TGF-β signaling results in increased 
COL7A1 expression in fibroblasts, keratinocytes, and mesenchymal stromal cells 
(Perdoni et al. 2014; Verrecchia et al. 2001; Vindevoghel et al. 1998). There are two 
Small Body Size and Mothers against decapentaplegic homologue (SMAD) TREs in the 
COL7A1 promoter. These sites exist at -490 and -435 bp in reference to the COL7A1 
TSS. TGF-β signaling can activate SMAD3/4 transcription factors leading to their 
translocation to the COL7A1 promoter where they bind the SMAD TREs and facilitate 
transcription. TGF-β signaling also cooperates with AP-1 to enhance expression of 
COL7A1(Verrecchia et al. 2001).  While TGF-β signaling is essential for wound healing 
and extracellular matrix production (ECM), the chronic TGF-β activation in RDEB skin 
may also be responsible for multiple aspects of RDEB pathology including fibrosis and 
higher incidence of squamous cell carcinoma (Jia et al. 2014; Li et al. 2015a; Oshimori et 
al. 2015; Qin et al. 2011).  Both may also be linked to the activity of a particular 
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microRNA(miR), miR-29, that regulates expression of various collagens as well as 
various genes associated with squamous cell carcinoma (Cushing et al. 2011; Liu et al. 
2010b; Qin et al. 2011; Yang et al. 2013). 
 
Figure 1: The COL7A1 Promoter.  The COL7A1 promoter annotated with the 
transcriptional response elements for SP1, SMAD, AP-1 and NF-κb and their relative 
locations. 
 
COL7A1 is also regulated at a transcriptional level by AP-1 activity.  AP-1 is a 
heterodimeric transcription factor composed of canonical Fos and Jun elements. AP-1 
binds AP-1 TREs, typically following activation via MAPK family signaling (Calonge et 
al. 2004; Florin et al. 2004). AP-1 was initially identified as a regulator of COL7A1 
transcription following activation from UV radiation (Nakano et al. 2001).  The AP-1 
TSS is -478 bp prior to the COL7A1 TSS. COL7A1 may also regulated via AP-1 through 
other activators of MAPK signaling, including injury, reactive oxygen species, or growth 
factors, although these aspects remain to be thoroughly characterized (Nagy et al. 2011; 
Tamai et al. 2011). AP-1 regulation of COL7A1 differs from SP1 and SMAD regulation 
in that AP-1 signaling appears to increase COL7A1 expression in fibroblasts while it 
reduces COL7A1 expression in keratinocytes (Kon et al. 2005). 
 IL-1β and TNF-α regulate COL7A1 expression during would healing.  Both 
cytokines regulate COL7A1 expression in a tissue specific manner; IL-1β and TNF-α 
signaling upregulates COL7A1 expression in dermal fibroblasts, but downregulates 
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expression in keratinocytes (Kon et al. 2005; Takeda et al. 2005).  Similarly to the 
cooperation between AP-1 and SMAD, SMAD transcription factors also cooperate with 
NF-κB following stimulation with TGF-β and TNF-α (Kon et al. 1999).  In contrast to 
COL1A1 regulation, NF-κB and SMAD are synergistic in this case.  The NF-κB TRE lies 
at -252 bp relative to the COL7A1 TSS. 
 While most regulation at the transcriptional level has focused on transcription 
factor binding in the core promoter region, COL7A1 is liked regulated epigenetically as 
well.  Specifically, there is good evidence that CpG islands within the COL7A1 gene have 
epigenetic states in certain cell lines, and hypermethylation may be responsible for 
silencing COL7A1 in mammary and prostate cancer cell lines (Chernov and Strongin 
2011).  It remains to be determined if a loss of COL7A1 expression contributes to 
mammary or prostate tumorigenesis. 
 Beyond transcriptional regulation, I propose that COL7A1 is also regulated at the 
post-transcriptional level by miR-29 (Vanden Oever et al. 2016). Beyond transcriptional 
control, there are several ways that collagen VII is regulated at a protein level. 
 
Type VII Collagen at the Protein Level 
Collagen VII contains 3 major protein domains: a non-collagenous domain 1 (NC1), a 
non-collagenous domain 2 (NC2) and in between them a central collagen domain 
(defined by repetitive Gly-X-Y repeats that constitute the canonical triple-helical region).  
This triple helical domain also contains a 39 amino acid hinge region that breaks the 
repeats (Richer and Seeger 2014).  The special nature of this protein allows for it to be 
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deposited in the extracellular space between epidermal and dermal layers and establish 
biochemical interactions that maintain adherence. 
Collagen VII is a relatively large extracellular matrix protein, and even prior to 
secretion it requires specialized proteins associated with the endoplasmic reticulum such 
as TANGO1 to be loaded into COPII vesicles (Saito et al. 2009).  TANGO1 binds C7 via 
its SH3 domain, and this type of transport is required for trimeric C7 secretion.  The C7 
protein is composed of a triple helical domain as well as flanking non-collagenous NC1 
and NC2 domains.  These domains are proteolytically cleaved prior to mature anchoring 
fibril formation. Upon secretion, C7 forms anti-parallel dimers, where two C7 trimers 
fuse their NC2 domains via disulfide bonds (Chen et al. 2001).  This allows for both ends 
of the NC1 domains to be available for interactions with basal keratinocytes.  Here, the 
NC1 domains interact with Laminin β3 on basal keratinocytes to help anchor the 
keratinocytes to the underlying dermis (Nakashima et al. 2005).  C7 interacts on the 
dermal side via biochemical and physical interactions with type I and IV collagens. This 
physical aspect has been previously described as being similar to Velcro in nature 
(Phimister et al. 2015).  C7 establishes the physical stability of the DEJ as well as 
orienting the keratinocytes near the DEJ during wound healing (Nyström et al. 2013b).  
C7 protein interactions play a large role in how cells near the DEJ interact with each 
other and regulate important functions such as wound healing. 
 
Type VII Collagen at a Cellular Level 
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The two major cell types of the dermis and the epidermis, dermal fibroblasts and 
epidermal keratinocytes, respectively primarily synthesize C7.  Beyond keratinocytes and 
fibroblasts there several other important cell types that play a role in immune and barrier 
function of the skin including Langerhans cells, Dendritic Epidermal T Cells, resident T 
cells, γδ T cells, Innate lymphoid cells, and Macrophages (Pasparakis et al. 2014).  
Keratinocytes are the primary cell type that composes the epidermis, and grow and 
mature through stages that make up the stratified squamous epithelium.  The first layer, 
stratum basale, contains basal keratinocytes which differentiate in an asymmetrical 
fashion (Williams et al. 2011).  Basal keratinocytes maintain their stemness through p63 
activity, a transcription factor which is also a suitable marker for identifying 
keratinocytes in the epidermis (Pellegrini et al. 2001; Senoo et al. 2007).  Basal 
keratinocytes then differentiate into various stages, which constitute the layers of the 
epidermis, including the stratum spinosum, the stratum granulosum and the stratum 
corneum; the latter constitutes keratinocytes at the most differentiated layer where dead 
keratinocytes are shed and replaced by keratinocytes at the lower layers (Simpson et al. 
2011). Basal keratinocytes not only synthesize C7 but also require C7 for proper 
polarization (Nyström et al. 2013b).  C7 maintains the correct organization of laminin 
332 and its corresponding signaling axis with integrin α6β4. In RDEB, loss of C7 reduces 
wound healing beyond the loss of structural integrity but also through disorganization of 
keratinocytes. 
C7 is also secreted by dermal fibroblasts, the most common cell found in the 
dermis.  Dermal fibroblasts produce ECM in the dermis, secreting growth factors and 
8 
 
regulating wound healing in the dermis and surrounding tissue.  The interactions between 
fibroblasts and keratinocytes are highly regulated, and keratinocyte secreted signals, 
including TGF-β, induce the differentiation of fibroblasts to myofibroblasts (Werner et al. 
2007).  Myofibroblasts are responsible for wound closure, with increased tensile strength 
and expression of smooth muscle actin. Beyond myofibroblasts, fibroblasts themselves 
are a somewhat heterogeneous cell type with a poorly defined phenotype and 
characteristics, and there may be other subsets of fibroblasts that have special roles in 
wound healing, scar tissue and fibrosis (Driskell et al. 2013).  Specialized fibroblasts also 
play distinct roles in the architecture of the dermis, and future therapies involving gene-
edited fibroblasts or fibroblasts injections would likely benefit from further 
characterization of these subsets (Kern et al. 2009b). 
 
RDEB Pathology: One cause with many consequences 
Beyond maintaining barrier function and mounting proper immune responses, another 
major role of skin is wound healing and tissue repair. Chronic wounds are a common 
problem for genodermatosis or other diseases such as diabetes, scleroderma and chronic 
infections (Bhattacharyya et al. 2014; Chen et al. 2014; Nyström et al. 2015). Wound 
healing is a coordinated process that occurs in well-timed phases, ultimately leading to 
re-epithelialization and wound closure. While the root cause of RDEB pathology is due to 
the lack of functioning anchoring fibrils, the complicated pathology of RDEB results 
from a cascade of responses to the constant injury and lack of sufficient repair to the DEJ.  
In particular, RDEB patients suffer from constant blistering and aberrant wound healing 
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which leads to fibrosis and eventually pseudosyndactyly of the digits (Moon et al. 2007).  
Based on evidence from mouse models of RDEB, it appears that the fibrosis is primarily 
driven through contractile fibrosis via increased infiltration of CD11+ cells in the dermis, 
increased TGF-β activity, and an increase in the overall number of myofibroblasts in the 
dermis; there were no overall defects with the bone structure of the extremities in these 
mice (Fritsch et al. 2008; Nyström et al. 2013a).  This fibrosis, driven by TGF-β and 
overexpression of ECM, is similar to other types of fibrosis that involve miR-29 (Cushing 
et al. 2011; Qin et al. 2011).  It remains to be seen whether miR-29 can be targeted or 
increased to reduce fibrosis, although reducing TGF-β activity and inflammation is 
effective in reducing fibrosis in an RDEB mouse model via Losartan treatment (Nyström 
et al. 2015).  
Persistent wound healing may also contribute to the permissive microenvironment that 
promotes the development of squamous cell carcinoma in RDEB patients (Guerra et al. 
2017; Mittapalli et al. 2016; Ng et al. 2012).  Along with issues in skin and mucosal 
membranes, RDEB pathology influences other tissues and cell types such as corneal 
abrasions, where C7 is also produced and required for the cornea to attach to the 
underlying tissue.  Beyond the aberrant immune responses there are also issues with 
peripheral neuropathy, which leads to an increased burden and pain in itch in patients that 
already suffer from constant blistering (Mack et al. 2014).  These patients also deal with 
other issues such a malnutrition and chronic infections.  These collective issues combined 
with the underlying defect make RDEB a strong candidate for cellular, genetic and 
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protein therapies that treat the underlying defect and would hopefully alleviate many if 
not all of the complications associated with a lack of functioning anchoring fibrils. 
Cellular Therapy for RDEB 
Cell therapy for RDEB includes the local injection of, or wound covering with, allogenic 
or genetically corrected skin cells, and mesenchymal or hematopoietic stem cell 
transplantation. Mouse studies demonstrated that fibroblast injections could potentially 
correct the RDEB phenotype and deposit C7 at the DEJ (Fritsch et al. 2008). For the use 
of fibroblast therapy to treat RDEB patients, allogenic fibroblasts were injected near sites 
of injury and subsequently analyzed for COL7A1 expression and C7 production, as well 
as clinical improvement (Venugopal et al. 2013). Based on clinical assessment, wound 
healing improved following fibroblast injections, although it was unclear as to whether 
that was due to functional C7 production or through another mechanism (Kern et al. 
2009b; Nagy et al. 2011; Petrof et al. 2013; Wong et al. 2008). Keratinocytes have also 
been used following genetic correction in ex-vivo model transplanted onto 
immunodeficient mice (Siprashvili et al. 2010).  This approach led to skin grafts that 
were viable and produced C7 for up to 1 year following engraftment.  This procedure was 
then adopted to a clinical setting where GMP-grade genetically corrected autologous 
epidermal sheets were grown and then applied to open wound of 4 patients with RDEB 
(Siprashvili et al. 2016).  This approach demonstrated improved wound healing at the site 
of the grafts up to 1 year after treatment.  However, both of these approaches were only 
efficient at treating RDEB locally, where mesenchymal stem cell or hematopoietic stem 
cell based-therapies may be more suitable for the systemic nature of RDEB. 
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 MSC therapy is an attractive approach to treating RDEB therapy because MSCs 
produce C7 and suppress immune responses, which may reduce the amount of 
inflammation and severity of RDEB (Fiorina et al. 2009; Sasaki et al. 2008).  MSCs can 
repair damaged tissue and produce C7 and other ECM proteins (Alexeev et al. 2011; Liu 
et al. 2008; Perdoni et al. 2014; Sasaki et al. 2008). In the context of RDEB patient 
therapy, MSC therapy was safe and effective in improving wound healing in 10 RDEB 
patients, although it is unclear as to whether there was a substantial increase in C7 
expression.  HCT has also shown promise to treat RDEB, and initial mouse studies 
demonstrated cells of hematopoietic origin, including CD150+/48- cells, homed to 
injured skin and secreted C7 near the DEJ (Tolar et al. 2009).  In human trials, following 
HCT there was an increase in C7 deposition and an improvement of symptoms in patients 
that received a successful engraftment (Wagner et al. 2010).  Similar studies investigating 
the ability of hematopoietic cells to treat injured skin demonstrated that a subset of bone 
marrow cells, PDGFRα+ cells, homed to injured skin, and responded to injury signals, 
specifically HMGB1 (Iinuma et al. 2015; Tamai et al. 2011).  
 Recently, multiple labs have developed and used induced pluripotent stem cells 
from patients of RDEB to study the disorder and to identify potential therapeutic 
approaches (Sebastiano et al. 2014; Tolar et al. 2013; Tolar et al. 2011).  RDEB induced 
pluripotent stem (iPS) cells can be genetically corrected and differentiated into multiple 
cell types including skin cells, such as keratinocytes, as well as mesenchymal stem cells 
and hematopoietic cells (Webber et al. 2016). Whether RDEB iPS cells will be useful in 
future therapies for treating RDEB is unclear, but it does demonstrate a meaningful proof 
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of principle that iPS cells can be made from RDEB patients and differentiated into cell 
types meaningful for future RDEB therapy. 
 
Gene Therapy for RDEB 
The most common form of gene therapy for treating genetic disorders uses viral vectors. 
Retroviral, lentiviral, and adenoviral vectors have been developed for RDEB gene 
therapy. Retroviral vectors were used to transduce fibroblasts, which were then evaluated 
and used for injection in a mouse model of RDEB. Transduced fibroblasts expressed 
functional C7, deposited it as mature anchoring fibrils, and provided improvement based 
on both in vitro and in vivo evaluations (Jacków et al. 2016). In similar studies, skin 
equivalents were also made from genetically corrected RDEB cells (Gache et al. 2004; 
Titeux et al. 2010). The first use of gene therapy for RDEB patients was a retroviral 
vector used to transduce keratinocytes containing full-length human COL7A1 
(Siprashvili et al. 2016). The transduced keratinocytes were then grown in a GMP facility 
to generate corrected epidermal sheets used for autologous therapy. All the autologous 
grafts were tolerated for 12 months, with positive outcomes, but alternative approaches 
will be needed to address the systemic problems of this disease. Adenoviral vectors were 
similarly used to correct RDEB cells, both fibroblasts and keratinocytes, and 
subsequently to establish iPSC lines for future therapeutic use (Sebastiano et al. 2014). 
Corrected iPSCs were then differentiated into keratinocytes that expressed C7 and 
developed stratified layers both in vitro and in vivo. Lentiviral vectors have also been 
developed for C7 gene therapy (Chen et al. 2002). Recently, a lentiviral vector was 
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developed containing a codon-optimized COL7A1 gene and used to correct RDEB 
fibroblasts (Georgiadis et al. 2016). Corrected fibroblasts expressed full-length, 
functional C7 in vitro and deposited C7 at the DEJ in skin grafts on immunodeficient 
mice.  
Non-viral strategies have also been developed for correcting RDEB cells, including the 
use of synthetic knot polymers for genetic transfection (Cutlar et al. 2016).  Synthetic 
knot polymers allow for efficient transfection and lower toxicity in comparison to 
standard transfection reagents.  Transfection of RDEB keratinocytes led to efficient 
expression of C7 in vitro. The use of non-viral-mediated gene therapy also includes 
transposons, such as Sleeping Beauty, to correct RDEB cells. Full length COL7A1 was 
recently inserted into RDEB keratinocytes via Sleeping Beauty transposons with stable 
integration (Latella et al. 2017). RDEB cells containing this cassette produced functional 
C7 in vitro and in vivo.  
Another non-viral approach for treating RDEB involves correcting parts of the mutated 
COL7A1 transcript through targeted exon skipping or trans-splicing. Exon skipping 
allows for truncated, functional C7 to be produced in RDEB cells through skipping of 
mutations in C7 in regions that are non-essential (Goto et al. 2006). Recent strategies 
include developing antisense ribonucleotides to target skipping of the mutated exon 73 or 
exon 80 of COL7A1 (Turczynski et al. 2016). This results in a portion of the mutated 
transcript being re-expressed and restoring partial C7 protein production. In vivo, these 
oligonucleotides can be injected into skin to restore anchoring fibril formation. Similarly, 
exon skipping was used to target exon 105, which also proved useful in an in vivo model 
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(Bremer et al. 2016). Another approach involves trans-splicing, which involves 
combining the original mutated COL7A1 pre-mRNA and a synthetic 3’ trans-splicing 
molecule that results in a full-length, functional COL7A1 mRNA (Murauer et al. 2011). 
Screening methods allow for assembly of trans-splicing constructs for particular types of 
RDEB-causing mutations (Tockner et al. 2016).  
Recent advances in gene editing can correct endogenous mutations and restore gene 
function in genetic disorders (Carroll 2011; Gaj et al. 2013; Reyon et al. 2012). For the 
treatment of epidermolysis bullosa, both TALEN and CRISPR/Cas approaches have been 
used to correct mutations in RDEB patient cells (Osborn et al. 2013; Webber et al. 2016). 
TALENs designed to correct a homozygous mutation in an RDEB patient fibroblast led 
to corrected C7 expression with no off-target effects. Corrected fibroblasts were capable 
of expanding long term in culture, as well as usable to derive corrected iPSC clones. A 
CRISPR/Cas gene editing strategy was also used to correct a mutation in COL7A1 in 
cultured RDEB fibroblasts. These cells were also used to make iPSC lines capable of 
being differentiated into keratinocytes, mesenchymal lineages, and hematopoietic 
lineages. Off-target effects with this approach were also limited. Similarly, an in vivo 
editing approach using CRISPR/Cas ribonucleoprotein corrected a COL7A1 mutation in a 
mouse model of RDEB by causing an in-frame deletion that restored function (Wu et al. 
2017). Although there are limitations to these approaches, they appear to have less 
inherent risk than previous approaches for gene therapy. Additionally, both the cost and 
time required to develop these tools are constantly shrinking. There are several non-
genetic approaches for treating RDEB, including aminoglycoside treatment, C7 protein 
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therapy, and modulating RDEB disease using a pharmacological approach such as 
losartan treatment that may prove useful in complementing gene therapy and stem cell 
approaches (Cogan et al. 2014; Hou et al. 2015; Nyström et al. 2015; Wang et al. 2013). 
 
Future Therapies for RDEB 
While stem cell and genetic therapies have shown promise for treating RDEB, it 
will likely take a combination of approaches to efficiently treat RDEB in a meaningful 
way. Furthermore, auxiliary approaches that target certain aspects of RDEB pathology, 
such as drugs to reduce fibrosis or limbal stem cells to treat corneal abrasions, may be 
needed to supplement primary therapies that are not universal in reducing RDEB 
pathology (Hayashi et al. 2012; Kern et al. 2009b; Nyström et al. 2015).  Beyond 
translational studies and human trials, there is also need to study the basic biology of 
RDEB including investigating the molecular mechanisms or squamous cell carcinoma in 
RDEB patients and regulation of COL7A1 in the context of wound healing in both 
healthy skin and RDEB skin (Pourreyron et al. 2007; Tsukada et al. 2012).  Finally, there 
is a need to do thorough studies of the trials themselves in order to understand the side 
effects of treatments that haven’t been used on RDEB patients as well as well-controlled 
studies to investigate the proper outcomes or biomarkers to properly evaluate the 
outcome of those trials. All of these studies will lead to not only effective therapies for 
RDEB but also a better understanding of RDEB pathology and the mechanisms by which 
the therapies treat RDEB. 
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Chapter 2: miR-29 Regulates Type VII Collagen in Recessive Dystrophic 
Epidermolysis Bullosa 
This section was published in the Journal of Investigative Dermatology: 
miR-29 Regulates Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa, 
Journal of Investigative Dermatology, Michael Vanden Oever, Daniel Muldoon, Wendy 
Mathews, Ron McElmurry, Jakub Tolar, Volume 136, Issue 10, October 2016, Pages 
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Abstract 
Recessive dystrophic epidermolysis bullosa (RDEB) is a complex inherited skin disorder 
caused by loss-of-function mutations in the COL7A1 gene. For an effective treatment of 
this disorder to be realized, both a thorough understanding of the regulation 
of COL7A1 and an understanding of the underlying nature of the complications of RDEB 
are needed. Currently, both posttranscriptional regulation of COL7A1 and the underlying 
causes of fibrosis in RDEB patients are poorly understood. Here, we describe a 
mechanism of regulation, to our knowledge previously unknown, by which micro RNA-
29 (miR-29) regulates COL7A1 in a complex network: both directly through targeting its 
3′ untranslated region at two distinct seed regions and indirectly through targeting an 
essential transcription factor required for basal COL7A1 expression, SP1. In turn, miR-29 
itself is regulated by SP1 activity and transforming growth factor-β signaling. RDEB 
mice express high levels of transforming growth factor-β and significantly lower miR-29 
compared with wild-type cohorts. The sustained decrease in miR-29 in RDEB skin leads 
to an increase of miR-29 target genes expressed in the skin, including profibrotic 
extracellular matrix collagens. Collectively, we identify miR-29 as an important factor in 
both regulating COL7A1 and inhibiting transforming growth factor-β–mediated fibrosis. 
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Introduction 
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe genetic skin disorder 
characterized by chronic skin blistering and abnormal wound healing (Nyström et al. 
2013b). Many long-term complications of RDEB are a result of systemic inflammation 
and contractile fibrosis due, in part, to an increase in transforming growth factor (TGF)-β 
signaling (Fritsch et al. 2008). Fibrosis leads to scarring, fusion of the digits and toes, and 
joint contractures. A number of cell-, protein-, and gene-based therapies are underway to 
correct the primary defect of RDEB, but even with their successes, the RDEB disease 
cascade, dominated by inflammation and fibrosis, will need additional therapies 
(Remington et al. 2009; Wagner et al. 2010). Further understanding of the biological 
mechanisms driving fibrosis in RDEB is required for any meaningful therapy. 
The underlying defect of RDEB is loss-of-function mutations in 
the COL7A1 gene, which encodes for the structural protein type VII collagen (C7)(Kern 
et al. 2009a). C7 is the major component of anchoring fibrils, the function of which is to 
establish and maintain structural adhesion between the dermis and the epidermis. C7 is 
produced in the skin by both keratinocytes and fibroblasts and then deposited at the 
dermal-epidermal junction, where it plays a major role in skin integrity and wound repair. 
Regulation of the COL7A1 gene in keratinocytes and fibroblasts occurs at the 
transcriptional level through SP1, a transcriptional factor that is responsible for basal 
expression of many genes lacking a canonical TATA box (Vindevoghel et al. 1997). 
Further regulation of COL7A1 occurs during various forms of skin injury and wound 
healing. On the transcriptional level, COL7A1 is up-regulated by TGF-β signaling via 
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SMAD3/4 activity (Vindevoghel et al. 1998). During inflammation, IL-1β or tumor 
necrosis factor-α signaling leads to an increase in COL7A1 expression in fibroblasts but a 
decrease in COL7A1 expression in keratinocytes (Kon et al. 2005). However, 
posttranscriptional regulation of COL7A1 in the context of wound healing and fibrosis is 
poorly understood. 
Fibrosis in other settings, such as pulmonary and renal fibrosis, is influenced by 
TGF-β activity (Qin et al. 2011). Pathological fibrosis in these settings is also heavily 
dependent on micro RNA (miR) activity, most importantly, miR-29 (Parker et al. 2014). 
The miR-29 family has been shown to regulate extracellular matrix during fibrosis: 
reduction in miR-29 levels results in an increase in extracellular matrix proteins, which 
subsequently leads to fibrosis. In most cases, TGF-β signaling is responsible for the 
reduction in miR-29 levels during fibrosis, and either targeting the TGF-β pathway or 
artificially increasing miR-29 activity in the context of fibrosis has been shown to reduce 
disease severity (Zhou et al. 2012). 
Here, we show that miR-29 directly regulates COL7A1 (in part via targeting the 3′ 
untranslated region [UTR]) and decreases SP1 expression (which leads to indirect 
regulation of COL7A1 transcription). We propose a mechanism whereby healthy wound 
healing in the skin leads to an increase in COL7A1 expression through TGF-β mediated 
repression of miR-29; whereas in the context of RDEB, pathological changes in TGF-β 
expression and long-term reduction in miR-29 levels promote fibrosis. 
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Results 
Identification of potential miR-COL7A1 interactions 
To identify miRs most relevant to COL7A1 regulation, we used miR-messenger RNA 
(mRNA) target prediction software. Bioinformatics software tools are a well-established 
approach for predicting miR-mRNA interactions in silico (Lewis et al. 2005). These 
prediction tools rely on established interactions between miRs and their respective 
mRNA targets (Friedman et al. 2009). This interaction involves a sequence of 6–8 base 
pairs in the mRNA target complementary to the 5′ end of the miR known as the seed 
region. Highly conserved seed regions in the 3′ UTR of an mRNA are hallmarks of 
genuine miR-mRNA interactions, representing evolutionary pressure to conserve miR 
regulation of a particular target mRNA. 
We used prediction software to investigate whether the 3′ UTR of COL7A1 showed any 
seed regions for known miRs, preferentially focusing on regions that were highly 
conserved among mammalian species. Targetscan software analysis (available 
at http://www.targetscan.org/) predicted two seed regions in the 3′ UTR of COL7A1 that 
are broadly conserved among mammalian species for miR-29 family members. These 
two seed regions (Figure 1a) are located at 77–84 base pairs and 290–296 base pairs of 
the COL7A1 3′ UTR. Both sites are complementary to the 5′ end of miR-29 and are 
predicted to base-pair with miR-29. Furthermore, miR-29 has been shown to be 
expressed in normal dermal fibroblasts (Cheng et al. 2013), cells found near the dermal-
epidermal junction where fibroblasts secrete C7 and other extracellular matrix 
components. We focused on miR-29 over other potential candidates for further analysis 
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because of the two predicted seed regions in the COL7A1 3′ UTR and prior studies 
showing miR-29 regulation of other collagens (Qin et al. 2011). 
 
22 
 
  
 
 
23 
 
Figure 1. miR-29 regulates COL7A1. (a) A schematic alignment between miR-29c and 
two regions of the COL7A1 3′ UTR: 63–84 base pairs and 275–297 base pairs, 
respectively. Alignment based on Targetscan miR-mRNA predictions. (b) Normal and (c) 
RDEB dermal fibroblasts as well as (d) normal and (e) RDEB keratinocytes were 
transiently transfected with miR-29 mimics. qRT-PCR analysis of COL7A1 expression 
relative to GAPDH expression 24 hours after transfection. n = 3. Values represent mean ± 
SE. ∗P < 0.05 (f) Normal and RDEB fibroblasts were transfected with miR-29 mimics 
and assayed for type VII collagen protein expression 72 hours after transfection. Blot was 
stained for type VII collagen and beta-actin as a loading control. (g) HEK-293 cells were 
co-transfected with a miR-29 mimic and a plasmid containing a firefly luciferase 
construct directly downstream of the COL7A1 3′ UTR and an independently 
regulated Renilla luciferase construct. Luciferase levels were measured 24 hours after 
transfection. Firefly luciferase levels were normalized to Renilla luciferase levels. n = 3. 
Values represent mean ± SE. ∗P < 0.05. (h) 293T cells were co-transfected with both a 
plasmid containing a firefly luciferase construct containing the COL7A1 3′ UTR region 
and an independently regulated Renilla luciferase construct in combination with a miR-
29 mimic. Luciferase levels were measured 24 hours after transfection. COL7A1 3′ UTR 
plasmids contained either wild-type sequences or mutations in either or both of the miR-
29 seed regions. Firefly luciferase levels were normalized to Renilla luciferase levels. 
Values represent mean ± SE. ∗P < 0.05 compared to the plasmid containing mutations in 
both sites 1 and 2. (i) HEK-293 cells were transiently transfected with miR-
29 COL7A1 3′ UTR target protectors for either of the predicted miR-29 seed regions on 
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the COL7A1 3’ UTR (Invitrogen, Waltham, MA); 24 hours after transfection, qRT-PCR 
analysis was performed to determine COL7A1 expression. qRT-PCR analysis 
of COL7A1 expression relative to GAPDH expression 24 hours after transfection. n = 3. 
Values represent mean ± SE. ∗P < 0.05. hsa, human; mml, rhesus; qRT-PCR, quantitative 
real-time reverse transcriptase–PCR; mmu, mouse; RDEB, recessive dystrophic 
epidermolysis bullosa; rho, rat; SE, standard error; UTR, untranslated region; 
WT, wild type. 
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miR-29 regulation of C7 
The miR-29 family consists of three miRs (miR-29a/b/c) synthesized at two different 
genomic loci on chromosomes 1 and 7 (Jiang et al. 2014). The mature forms of each 
miR-29 (3′) species share the same 5′ sequence necessary for sequence-specific miR-
mRNA interaction and consequently share overlapping function in regulating specific 
mRNA targets. It has been previously reported that miR-29 is responsible for regulating 
expression of multiple collagens, including COL1A1, COL1A2, COL3A1, COL4A1, 
COL5A1, COL5A2, COL15A1 (Cheng et al. 2013; Liu et al. 2010a; Luna et al. 2009; 
Yang et al. 2013). Given this information and the results from target prediction software, 
we sought to determine whether miR-29 was capable of regulating COL7A1. To 
investigate this, we transfected synthetic mimics of miR-29 into dermal fibroblasts and 
assayed them for COL7A1 expression using quantitative real-time reverse transcriptase–
PCR (qRT-PCR) 24 hours after transfection. Transfection of dermal fibroblasts and 
keratinocytes with miR-29 mimics led to a decrease in COL7A1 expression levels 
compared with mimic controls (Figure 1b–e). We observed similar results when 
measuring C7 protein after miR-29 mimic transfection as well (Figure 1f). This shows 
that miR-29 activity inhibits COL7A1 expression. 
To further define the relationship between COL7A1 and miR-29, we aimed to determine 
whether the regulation of miR-29 on COL7A1 was direct or indirect, because previous 
studies have shown that miR-29 is capable of regulating other collagens either directly or 
indirectly. For example, in pulmonary fibrosis miR-29 has been shown to directly 
target COL1A1 via interaction with its 3′ UTR (Cushing et al. 2011). Conversely, in renal 
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fibrosis miR-29 was shown to indirectly increase type I collagen production through the 
targeting of SP1, a transcription factor required for basal expression of COL1A1(Chen et 
al. 2014; Cheng et al. 2013; Jiang et al. 2013). To determine whether miR-29 was capable 
of targeting the COL7A1 transcript, we generated luciferase reporter plasmids containing 
the 3′ UTR of COL7A1. Co-transfection of 293T cells with the COL7A1 3′ UTR reporter 
plasmid and synthetic miR-29 mimics led to a decrease in firefly luciferase activity 
compared with mimic controls (Figure 1g). This shows that miR-29 is capable 
of regulating COL7A1, at least in part through direct interactions with its 3′ UTR. 
Because miR-29 is predicted to interact with the COL7A1 3′ UTR at two distinct seed 
regions (Figure 1a), we wished to determine how these seed regions mediate miR-29 
regulation of C7. To that end, we generated reporter constructs in which either or both of 
the seed regions were mutated to disrupt the predicted base-pairing between miR-29 and 
the 3′ UTR complementary sequence. Mutations in either of the seed sequences reduced 
the effect of miR-29 on the COL7A1 3′ UTR reporter construct, whereas mutations in 
both seed sequences abolished miR-29’s effect on the COL7A1 3′ UTR reporter 
altogether (Figure 1h). We found no significant differences in luciferase levels between 
experiments in which miR-29 seed sequence 1 was mutated versus the reporter construct 
in which seed sequence 2 was mutated. This shows that both miR-29 seed sequences in 
the 3′ UTR of COL7A1 are required in regulating COL7A1 expression. 
To further examine the functional specificity of each of the miR-29 seed sequences 
in COL7A1, we utilized 3′ UTR target protectors. These synthetic oligonucleotides 
consist of a single-stranded RNA molecule that is complementary to the 3′ UTR of 
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interest. Specifically, we developed two distinct target protectors that effectively masked 
each seed region required for direct miR-29 regulation of the COL7A1 transcript. Upon 
transfection of these target protectors into dermal fibroblasts, we saw a dose-dependent 
increase in COL7A1 expression compared with non-transfected controls (Figure 1i). 
Collectively, these data show that miR-29 regulates C7 through directly targeting its 3′ 
UTR and confirm that both seed regions contribute to miR-29 regulation of C7. 
 
miR-29 regulates COL7A1 indirectly via targeting its transcription factor SP1 
Previous studies have shown that miR-29 is capable of negatively regulating SP1 (Jiang 
et al. 2013). miR-29 has been shown to regulate COL1A1 directly in fibroblasts 
associated with fibrosis and indirectly through SP1 in renal tubular epithelial cells (Cheng 
et al. 2013; Jiang et al. 2013). SP1 is a ubiquitously expressed transcription factor 
required for basal transcription of COL7A1; therefore factors that 
influence SP1 transcriptional activity are capable of indirectly 
influencing COL7A1 expression (Vindevoghel et al. 1997). To investigate whether miR-
29 was capable of regulating SP1, we transfected normal and RDEB dermal fibroblasts 
with synthetic mimics of miR-29 and assayed SP1 gene expression 24 hours after 
transfection. Transfection of dermal fibroblasts with miR-29 mimics led to a decrease 
in SP1 expression levels compared with controls (Figure 2a and b). To further refine the 
mechanism of SP1 regulation by miR-29, we used a reporter that contains five tandem 
repeats of the SP1 transcriptional response element and thus directly reflects the 
transcriptional activity of SP1. When we co-transfected this reporter construct with miR-
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29 mimics, we saw a decrease in relative luciferase activity (Figure 2c). Conversely, 
when we co-transfected this reporter with inhibitors of miR-29, we saw an increase in 
luciferase activity (Figure 2c). This confirms that miR-29 is capable of regulating genes 
indirectly through targeting the transcription factor SP1. 
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Figure 2. SP1 and miR-29 co-regulate each other and COL7A1. (a) Normal and (b) 
RDEB dermal fibroblasts were transfected with miR-29 mimics. qRT-PCR analysis 
of SP1 expression relative to GAPDH expression 24 hours after transfection. n = 3. 
Values represent mean ± SE. ∗P < 0.05. (c) 293T cells were transiently co-transfected 
with a luciferase reporter assay containing tandem repeats of the SP1 transcriptional 
response element in combination with either miR-29 mimics or inhibitors (Invitrogen, 
Waltham, MA). Luciferase levels were measured 24 hours after transfection. Firefly 
luciferase levels were normalized to Renilla luciferase levels. n = 3. Values represent 
mean ± SE. ∗P < 0.05. (d) 293T cells were transfected with an SP1 overexpression vector 
for 24 hours. qRT-PCR analysis of miR-29 levels was performed relative to U6 levels. 
n = 3. Values represent mean ± SE. ∗P < 0.05. (e) Normal and (f) RDEB fibroblasts were 
transiently transfected with SP1 small interfering RNA for 48 hours. qRT-PCR analysis 
of miR-29 levels was performed relative to U6 levels. n = 3. Values represent mean ± 
SE. ∗P < 0.05. (g) Normal and (h) RDEB fibroblasts were treated with mithramycin A (an 
inhibitor of SP1 binding) for 48 hours. qRT-PCR analysis of miR-29 levels was 
performed relative to U6 levels. n = 3. Values represent mean ± SE. ∗P < 0.05. Inhibition 
of SP1 binding decreases COL7A1 and SP1 expression. (i) Normal and (j) RDEB 
fibroblasts were treated with mithramycin A (an inhibitor of SP1 binding) for 48 hours. 
qRT-PCR analysis of COL7A1 and SP1 levels was performed relative to GAPDH. n = 3. 
Values represent mean ± SE. ∗P < 0.05. miR, micro RNA; RDEB, recessive dystrophic 
epidermolysis bullosa; qRT-PCR, quantitative real-time reverse transcriptase–PCR; SE, 
standard error; siRNA, small interfering RNA. 
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SP1 and miR-29 exhibit a co-inhibitory loop 
Previous studies have shown that SP1 is capable of negatively regulating miR-29 
expression (Li et al. 2012; Liu et al. 2010b). To determine if SP1 regulates miR-29, we 
transfected 293T cells with an SP1-expression cassette and measured miR-29 levels 24 
hours after transfection. Transfection with the SP1 cassette led to a decrease in miR-29 
levels (Figure 2d). Conversely, transfection with a short interfering RNA targeting SP1 
led to an increase in miR-29 levels (Figure 2e and f), showing that SP1 regulates miR-29. 
To further delineate the roles of SP1 and miR-29 in regulation of COL7A1, we used 
Mithramycin A, which binds to guanine-cytosine–rich sequences and subsequently 
inhibits the binding and activity of SP1 (Sleiman et al. 2011). Normal and RDEB 
fibroblasts treated with Mithramycin A showed increased miR-29 expression (Figure 2g 
and h). Conversely, when normal and RDEB fibroblasts were treated with Mithramycin 
A, we saw a decrease in both SP1 and COL7A1 expression (Figure 2i and j). These data 
show a negative regulatory loop by which miR-29 targets SP1 and leads to a decrease 
in SP1 expression and activity, whereas SP1 transcriptional activity leads to a decrease in 
miR-29 levels. Furthermore, because both SP1 and miR-29 are capable of 
regulating COL7A1 expression, changes in miR-29 or SP1 levels could amplify changes 
in COL7A1 expression because of changes in the miR-29/SP1 regulatory loop. 
 
miR-29 levels are decreased in RDEB skin 
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Hallmarks of the phenotype of RDEB in the skin include chronic skin blistering and 
scarring with nonproductive wound healing. This is pronounced in the extremities, where 
the progression of chronic blistering in the digits leads to pseudosyndactyly. 
Characterization of these regions showed TGF-β accumulation and aberrant contractile 
fibrosis in the dermis of Col7aflNeo/flNeo mice (Fritsch et al. 2008). Treatment of the 
RDEB mouse model using losartan led to a decrease in TGF-β signaling and a reduction 
in fibrosis and fusion of the digits (Nyström et al. 2015). Based on the work of others 
identifying miR-29 as a key player in TGF-β–mediated fibrosis (Cushing et al. 2011; Qin 
et al. 2011; van Rooij et al. 2008), we set out to determine the levels of miR-29 in RDEB 
skin compared with in healthy controls. We found that the miR-29 levels were 
significantly lower in skin isolated from COL7A1flNeo/flNeo mice versus wild-type 
controls (Figure 3). 
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Figure 3. COL7A1flNeo/flNeo homozygous mice exhibit reduced miR-29 
expression. Small RNA was isolated from skin samples from both COL7A1flNeo/flNeo mice 
and wild-type controls. qRT-PCR analysis of miR-29 levels was performed relative 
to U6 levels. n = 3. Values represent mean ± SE. ∗P < 0.05. miR, micro RNA; qRT-PCR, 
quantitative real-time reverse transcriptase–PCR; SE, standard error; WT, wild type. 
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miR-29 is down-regulated in normal dermal and RDEB fibroblasts and 
keratinocytes via TGF-β signaling 
C7 expression is increased in response to injury to the skin (Nakano et al. 2001; 
Vindevoghel et al. 1998). In particular, C7 expression has been shown to increase after 
activation of the TGF-β pathway (Vindevoghel et al. 1998). TGF-β signaling leads to 
phosphorylation of downstream effector SMAD proteins, of which activated SMAD3 and 
-4 bind to COL7A1 promoter and promote COL7A1 transcription. Furthermore, TGF-β 
activation influences RDEB disease severity through increased type 1 collagen and 
decreased decorin expression (Odorisio et al. 2014). Previous studies have also shown 
that TGF-β signaling results in a decrease in miR-29 expression through inhibition of 
transcription via binding of SMAD3 to the miR-29 promoter region (Qin et al. 2011; 
Zhou et al. 2012). SMAD activity on the miR-29 promoter region results in a decrease of 
the primary (pri) miR as well as downstream mature miR levels. Therefore, we sought to 
investigate if miR-29 levels changed in response to TGF-β in normal and RDEB 
fibroblasts and keratinocytes. After exposure of normal and RDEB dermal fibroblasts and 
keratinocytes to TGF-β1, miR-29 levels decreased compared with untreated controls 
(Figure 4a–d). To determine if primary miR-29 levels were decreased in RDEB and 
normal fibroblasts after TGF-β exposure, we exposed RDEB fibroblasts for 24 hours and 
subsequently assayed for primary miR-29 levels. After exposure to TGF-β1, we saw a 
decrease in pri-miR-29A, pri-miR-29B1, pri-miR29-B2, and pri-miR-29C levels 
(Figure 4e and f). To further investigate whether endogenous levels of TGF-β signaling 
were sufficient for miR-29 regulation, we used small interfering RNA knockdown of 
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both TGFB1 and its downstream transcription factor, SMAD3. Upon transfection of 
both TGFB1 (Figure 4g and h) and SMAD3 (Figure 4i and j) knockdown we see an 
increase in miR-29 levels 48 hours after transfection. Furthermore, inhibition of TGF-β 
receptor signaling by use of a TGF-β receptor inhibitor (SB431542) results in an increase 
in miR-29 levels 24 hours after treatment (Figure 4k and l). In vivo, however, TGF-β 
injection did not result in a significant decrease in miR-29 levels. This is likely due to 
multiple factors in RDEB skin contributing to miR-29 regulation and prolonged TGF-β 
signaling (see Supplementary Figure S1 online). These data show that TGF-β signaling 
reduces miR-29 levels, which indirectly increases COL7A1 levels through de-repression 
of miR-29 regulation. Furthermore, they show that TGF-β signaling 
alters COL7A1 expression at both the transcriptional and posttranscriptional levels. This 
is further enhanced through the activity of SP1, both through COL7A1 transcription and 
miR-29 inhibition (Figure 5). 
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Figure 4. TGF-β down-regulates miR-29. Both (a) normal and (b) RDEB fibroblasts as 
well as (c) normal and (d) RDEB keratinocytes were treated with TGF-β1 for 24 hours. 
qRT-PCR analysis of miR-29 levels was performed relative to U6 levels. n = 3. Values 
represent mean ± SE. ∗P < 0.05. (e) Normal and (f) RDEB fibroblasts were treated with 
TGF-β1 for 24 hours. qRT-PCR analysis of primary miR-29 levels relative 
to GAPDH levels. n = 3. Values represent mean ± SE. ∗P < 0.05. (g) Normal and (h) 
RDEB fibroblasts were transiently transfected with TGF-β1 siRNA for 48 h. Quantitative 
RT-PCR analysis of miR-29 levels relative to U6 levels. N = 3. Values represent mean ± 
SE. ∗P < 0.05. (i) Normal and (j) RDEB fibroblasts were transiently transfected with 
SMAD3 siRNA for 48 hours. qRT-PCR analysis of miR-29 levels was performed relative 
to U6 levels. n = 3. Values represent mean ± SE. ∗P < 0.05. (k) Normal and (l) RDEB 
fibroblasts were treated with a TGF-β1 receptor inhibitor, SB431542. qRT-PCR analysis 
of miR-29 levels was performed relative to U6 levels. n = 3. Values represent mean ± 
SE. ∗P < 0.05. miR, micro RNA; RDEB, recessive dystrophic epidermolysis bullosa; 
qRT-PCR, quantitative real-time reverse transcriptase–PCR; SE, standard error; siRNA, 
small interfering RNA; TGF, transforming growth factor. 
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Figure 5. miR-29 regulation of COL7A1. A schematic diagram illustrating miR-29 
regulation of COL7A1. miR-29 regulates COL7A1 directly through two seed sequences in 
the COL7A1 3′ untranslated region as well as indirectly through regulating its basal 
transcription factor, SP1. SP1 and miR-29 regulate each other in a negative fashion, 
establishing a co-inhibitory loop. During wound healing, TGF-β signaling leads to 
phosphorylation and activation of downstream SMAD transcription factors, which results 
in a subsequent decrease in miR-29 levels and an increase 
in SP1 and COL7A1 expression. TGF, transforming growth factor; miR, micro RNA. 
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Supplementary Figure S1: miR-29 expression following TGF-β injection in wild-
type mice. Mice were injected subcutaneously with 800 ng of recombinant TGF-β1 daily 
for 3 consecutive days. 24 h following the last injection, skin samples were taken from 
the injection site and assayed for miR-29 expression. Quantitative RT-PCR analysis of 
miR-29 levels relative to U6 levels. N = 3. Values represent mean ± SE. RT-PCR, reverse 
transcriptase PCR; SE, standard error. 
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Discussion 
Previous reports have focused on the role of COL7A1 expression at the transcriptional 
level. Here, we show a mechanism by which COL7A1 is regulated at the transcriptional 
and posttranscriptional levels by miR-29. Further, we confirm that TGF-β signaling 
results in a decrease in miR-29 levels, antagonizing regulatory control of miR-29 
on COL7A1 and leading to de-repression of COL7A1. This regulation is coupled with an 
indirect regulation of miR-29 on COL7A1 through regulation of its basal transcription 
factor SP1. SP1 and miR-29 act in a negative co-regulatory loop that is perturbed by 
TGF-β signaling. Reduction of miR-29 in response to TGF-β signaling likely functions in 
skin homeostasis to increase extracellular matrix production during wound healing and 
re-epithelialization. 
C7 plays a crucial role in both maintaining structural integrity of the skin and assisting in 
wound closure (Nyström et al. 2013b). Therefore, increasing C7 expression at both the 
transcriptional and posttranscriptional levels would be beneficial for tissue repair. 
However, prolonged reduction in miR-29 levels may also lead to complications such as 
the fibrosis that leads to joint contractures and pseudosyndactyly (Qin et al. 2011; Zhou 
et al. 2012). A mouse model for RDEB has shown an increase in TGF-β1 in RDEB skin, 
resulting in an accumulation of myofibroblasts in the extremities, which is responsible for 
driving contractile fibrosis in the digits (Fritsch et al. 2008). This is likely further 
exacerbated by a reduction in miR-29, which leads to an increase in multiple collagens, 
mainly COL1A1 and COL3A1. Furthermore, prolonged reduction in miR-29 levels may 
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promote an increase in other miR-29 targets associated with the development of 
squamous cell carcinoma, such as MMP2 and SP1 (Jia et al. 2014; Lu et al. 2014). 
In the context of wound healing, miR-29 is among a host of other miRs in the skin that 
regulate the wound healing process. During wound healing, miR-21 has been shown to 
regulate migration and re-epithelialization of keratinocytes within the wound bed (Yang 
et al. 2011). Also, miR-31 has also been shown to regulate keratinocyte proliferation and 
migration, although through regulating a different set of genes than miR-21 (Li et al. 
2015b). In this respect, miR-29 is among a network of other miRs that likely function in 
concert to regulate various aspects of wound healing, and how these miRs function 
together remains to be seen. Also, there are likely other miRs that are capable of 
regulating COL7A1, as well as other miRs that are dysregulated in the context of RDEB 
and may play a role in RDEB pathology as well. 
Although understanding COL7A1 regulation of miR-29 in the context of RDEB is 
important to understanding the disease pathology and nature of RDEB, understanding 
how other targets of miR-29 are expressed in the context of RDEB may prove to be 
useful as well (Küttner et al. 2013). In the context of fibrosis, it is likely that dermal 
collagens such as COL1A1 and COL3A1 play a major role in fibrosis and are influenced 
by miR-29 regulation. Furthermore, miR-29 has been shown to influence 
DNA methylation through targeting TET1 and TDG (Morita et al. 2013) as well 
as DNMT3A, DNMT3B, and DNMT1 (Garzon et al. 2009). Whether there are any 
significant changes in DNA methylation in RDEB remains to be seen, but if other miR-
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29 targets are regulated in the skin in similar fashion to COL7A1 and SP1, there is likely 
to be dysregulation of DNA methylation in RDEB because of miR-29 activity. 
Ideally, therapies for RDEB will result in an increase in functional, stable anchoring 
fibrils while reducing the amount of fibrosis and the incidence of squamous cell 
carcinoma. Future clinical applications focused on increasing functional C7 in RDEB 
skin through manipulation of miR-29 will require a targeted approach by separating miR-
29 regulation of COL7A1 versus reducing overall miR-29 levels. 
Specifically, COL7A1 target protectors, which disrupt miR-29 regulation 
of COL7A1 without interfering with miR-29 regulation of other targets genes, may be the 
preferred approach. Furthermore, miR-29 may be a suitable biomarker for overall skin 
integrity, and measuring miR-29 levels of the skin of RDEB patients may be an indicator 
for fibrosis. 
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Materials and Methods 
Cell culture   
RDEB, normal human dermal fibroblasts, and HEK-293T cells were maintained in 
DMEM supplemented with 10% fetal bovine serum, 100 U/ml nonessential amino acids, 
and 0.1 mg/ml each of penicillin and streptomycin (Invitrogen, Carlsbad, CA). Normal 
and RDEB keratinocytes were maintained in Epilife medium supplemented with 60 
μmol/L calcium, 1% Epilife Defined Growth Supplement, and 1% 
gentamicin/amphotericin solution (Invitrogen, Carlsbad, CA). 
Inhibitors 
Mithramycin A (150 ng/ml, GR305-0001, VWR Scientific, Radnor, PA) or SB431542 
(10 μmol/L, S-4317, Sigma-Aldrich, St. Louis, MO) were added directly to fibroblast 
media, and cells were incubated for 24–48 hours before RNA or small RNA isolation. 
Fibroblast transfection 
RDEB and normal human dermal fibroblasts, as well as RDEB and normal keratinocytes, 
were transiently transfected using the Neon Transfection System (Invitrogen). A total of 
2 × 105 fibroblasts were transfected with either 90 pmol of miRvana miRNA mimic 
(miR-29a, miR-29b, miR-29c, or mimic control; Invitrogen) or miRvana miRNA 
inhibitor (miR-29a, miR-29b, miR-29c, or mimic control; Invitrogen) or small interfering 
RNA select (TGF-β1:s14056, SMAD3:s8402, and SP1:s13320) using the following 
settings: 1,500 V, 20-milisecond pulse width, 1 pulse. A total of 2 × 105 keratinocytes 
were transfected with 90 pmol of miRvana mimics using the following settings: 850 V, 
30-milisecond pulse width, 2 pulses. 
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293T transfection 
A total of 2.5 × 105 HEK-293T cells were transiently transfected using Lipofectamine 
2000 reagent (Invitrogen). For the luciferase assays, 1 μg of each luciferase reporter was 
used in combination with either 90 pmol of miR-29 miRvana mimic or inhibitor. For the 
target protector assays, either a target protector control or various concentrations (50 
pmol, 100 pmol, and 200 pmol) of miScript Target Protector (Qiagen, Valencia, CA), 
which were designed to mask either the first or second mir-29 seed sequence in 
the COL7A1 3′ UTR, were used for transfection. The sequence 
for COL7A1 target protector 1 was 
CCCACTGTCCCTCCCCTTGGTGCTAGAGGCTTGTGTGCAC and 
for COL7A1 target protector 2 was 
CCAAGCCTGTGATGACATGGTGCTGATTCTGGGGGCATT. 
RDEB mouse strain miR analysis 
All animal studies were approved by the University of Minnesota Institutional Animal 
Care and Use Committee. The RDEB hypomorphic mouse model, C57Bl/6-
TgH(COL7A1flNeo)288LBT, was used for microRNA analysis (Fritsch et al., 2008). 
Full-thickness skin samples were isolated from RDEB hypomorphic pups and wild-type 
littermate controls. Samples were placed in RNAlater (Qiagen) before small RNA 
extraction. Skin samples were first processed using a Tissue-Tearor rotor/stator 
homogenizer (Biospec, Racine, WI) for 1 minute in mirPremier (Sigma-Aldrich, St. 
Louis, MO) miR lysis buffer before small RNA isolation. 
TGF-β injection 
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C57Bl/6 wild-type mice were injected with 800 ng of carrier-free mouse TGF-β1 (Cell 
Signaling Technology, Danvers, MA) resuspended in 20 μl phosphate-buffered saline. 
Injections were done with a microneedle subcutaneously in the neck of neonatal mice. 
After 3 daily injections, skin samples were taken from the injection site and processed as 
described for small RNA isolation. 
qRT-PCR 
RNA was isolated using the RNeasy Plus Mini Kit (Qiagen). Subsequent first strand 
complementary DNA synthesis was performed using the SuperScript Vilo cDNA 
Synthesis Kit (Invitrogen). qRT-PCR was performed using Taqman Gene Expression 
Assays and Taqman Universal Master Mix II, no Uracil-N-Glycosylase (Invitrogen). 
qRT-PCR was performed on the StepOnePlus Real-Time PCR System (Applied 
Biosystems, Waltham, MA). The Taqman Gene Expression assays used 
were COL7A1 (Hs00164310_m1), SP1 (Hs00916521_m1), miR-29a-pri 
(Hs03302672_pri), miR-29b1-pri (Hs03302748_pri), miR-29b2-pri (Hs03302750_pri), 
and miR-29c-pri (Hs04225365_pri). Glyceraldehyde-3-phosphate dehydrogenase 
(Hs02758991_g1) was used as an endogenous control. Small RNA from mouse skin 
samples and cell culture was isolated using the mirPremier microRNA Isolation Kit 
(Sigma-Aldrich). Micro RNA was reverse transcribed using the Taqman MicroRNA 
Reverse Transcription Kit (Invitrogen). The following Taqman Micro RNA assays used 
were: miR-29a (002112), miR-29b (000413), and miR-29c (00587). U6 (001973) was 
used as a positive control. 
Immunoblot 
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Normal and RDEB fibroblasts transfected with miR-29 mimics or controls as stated were 
incubated for 72 hours before cell lysis. Cells were lysed in radioimmunoprecipitation 
assay buffer containing a protease inhibitor cocktail (Sigma-Aldrich). Lysates were 
clarified and measured for protein concentration using a bicinchoninic acid protein assay 
before loading. Equal quantities of protein were loaded onto 3–8% Tris-acetate gel. After 
electrophoresis, protein was transferred onto a nitrocellulose membrane and incubated 
with anti-C7 antibody (a kind gift provided by David Woodley and Mei Chen) or anti–
beta-actin (A2228, Sigma-Aldrich) antibody overnight. The following day, membranes 
were incubated with goat anti-rabbit horseradish peroxidase-conjugated secondary 
antibody (sc-2005, Santa Cruz Biotechnology, Santa Cruz, CA). After incubation with 
secondary antibody, blots were developed using SuperSignal West Pico 
Chemiluminescent Substrate (ThermoFisher Scientific, Waltham, MA) and developed on 
X-ray film for imaging. 
Luciferase reporter plasmids 
Luciferase plasmid reporter constructs containing both the wild-type sequence of 
the COL7A1 3′ UTR or mutant derivatives containing changes in either or both of the 
miR-29 seed sequences were developed using the pMIRglo Dual Luciferase Vector 
(Promega, Madison, WI). MiR-29 seed sequences (Figure 1) were mutated as follows: 
UGGUGCU to ACCACGA for both site 1 and site 2. 
Statistics 
All data are presented as mean ± standard deviation of three independent biological 
replicates or more. Student t test was used to determine the significance between two 
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groups or between an experimental variable and a control. P-values less than or equal to 
0.05 were considered statistically significant. 
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Chapter 3: Fludarabine modulates expression of type VII collagen during 
hematopoietic stem cell transplantation for recessive dystrophic epidermolysis 
bullosa 
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ABSTRACT 
Recessive dystrophic epidermolysis bullosa is a severe, complicated disorder with few 
treatment options currently available. Recently, hematopoietic stem cell transplantation 
(HCT) has been used as an alternative therapy. Although some patients have seen 
improvement, the mechanisms involved have not been thoroughly characterized. We 
uncovered a previously unknown consequence of fludarabine, one of the chemotherapy 
drugs in the HCT preparative regimen, whereby dermal fibroblasts exposed to 
fludarabine upregulate type VII collagen. This effect is mediated in part through 
activation of the MAPK/ERK and P13K/AKT pathways. Activation of these pathways 
leads to activation of downstream transcription factors, including AP-1. Subsequently, 
AP-1 binds the COL7A1 promoter and increases COL7A1 expression. This finding 
highlights the complex nature of the side effects associated with the HCT process and the 
need to investigate each aspect of the HCT preparative regimen to understand how it 
influences both outcomes and the clinical evaluation of those outcomes.  
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INTRODUCTION 
Recessive dystrophic epidermolysis bullosa (RDEB) is a life-threatening genetic skin 
disorder that results in skin fragility and severe blistering. RDEB patients suffer from 
painful symptoms including esophageal strictures, mitten deformities, corneal abrasions, 
and severe itching (Kirkorian et al. 2013; Mack et al. 2014). The severity of RDEB is 
compounded by chronic infections and early development of an aggressive form of 
squamous cell carcinoma that typically develops later in life (Ng et al. 2012; Pourreyron 
et al. 2007). There is currently no cure for RDEB, although significant progress in 
treating this disorder has been made using cellular, genetic, and protein therapies (Osborn 
et al. 2013; Wagner et al. 2010; Webber et al. 2016; Woodley et al. 2013). Specifically, 
hematopoietic stem cell transplantation (HCT) has recently been used as an alternative 
therapy and may be effective in treating the systemic nature of the disease. However, 
much about the use of HCT to treat RDEB is unknown, including potential RDEB-
specific side effects.  
 
RDEB is an inherited disorder where loss-of-function mutations in the gene COL7A1, 
which encodes for type VII collagen (C7), result in structural deficiency in the skin. C7 is 
the main component of anchoring fibrils, which are required for the epidermis to adhere 
to the dermis. In the case of RDEB, absence or impaired function of C7 leads to absent or 
structurally defective anchoring fibrils and extreme fragility in skin architecture 
(Järvikallio et al. 1997). C7 is produced by keratinocytes and fibroblasts in the dermis, 
where C7 is then deposited at the dermal-epidermal junction (DEJ). Other cells types, 
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such as mesenchymal stem cells and other hemogenic cells, may be capable of homing to 
injured skin and depositing C7 at the DEJ as well (Conget et al. 2010; Tamai et al. 2011; 
Tolar et al. 2009; Wagner et al. 2010). During inflammation, dermal fibroblasts respond 
to signals such as IL-1β and TNFα by increasing COL7A1 expression (Takeda et al. 
2005). Fibroblasts, keratinocytes, and mesenchymal stem cells also respond to TGF-β 
signaling by increasing COL7A1 expression at both transcriptional and post-
transcriptional levels (Vanden Oever et al. 2016; Verrecchia et al. 2001; Vindevoghel et 
al. 1998). Furthermore, dermal fibroblasts upregulate COL7A1 upon exposure to 
ultraviolet (UV) light. This upregulation is mediated through activation of the AP-1 
transcription factor, which binds to an AP-1 response element in the COL7A1 promoter 
(Nakano et al. 2001). Most studies investigating the regulation of COL7A1 have focused 
on skin responses to injury or inflammation; however, COL7A1 regulation in response to 
drugs, including those used in chemotherapy, remains only partially understood. This is 
of utmost importance in the context of HCT due both to the ability to effectively measure 
the presence of functional vs non-functional C7 and to the potential for non-functional, 
truncated C7 to compete with functional C7 at the DEJ and disrupt the benefits of the 
therapy. 
 
The use of HCT to treat RDEB is a relatively new approach. HCT has shown promising 
results as initial studies have demonstrated the ability of engrafted stem cells to produce 
long-term, systemic distribution of functional C7. , However, HCT requires immune 
suppression, which can be risky for RDEB patients (Geyer et al. 2015; Wagner et al. 
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2010). The HCT preparatory regimen uses cytotoxic drugs including busulfan, 
cyclophosphamide, and fludarabine that may have effects on RDEB skin, beneficial or 
otherwise, that are not currently known (Bonin et al. 2007; Bornhäuser et al. 2003; 
Reimer et al. 2012). Fludarabine purpose in the HCT preparative regimen is to act both as 
a cytotoxic and immunosuppressive drug. However, other cell types have shown a wide 
variety of responses—including activation, differentiation, and growth arrest—as well as 
altered gene expression following fludarabine treatment (Eissner et al. 2002; Jiang et al. 
1992; Nishioka et al. 2008). Fludarabine treatment enhances expression of both ICAM-1 
and IL-8 in U937 cells (Fernández-Calotti et al. 2006). This increased expression was 
shown to be partially regulated through activation of the MAPK/ERK pathway and 
subsequent increase in AP-1 transcriptional activity. Other studies have demonstrated that 
fludarabine increased levels of reactive oxygen species (ROS) production, which is also 
associated with an increase in MAPK/ERK activation (Maggio et al. 2004). Side effects 
from the response of non-hematopoietic cells to chemotherapy may play an important 
role in both clinical outcomes of newer therapies and the biomarkers by which we 
measure them. 
 
Here, we demonstrate that fludarabine treatment results in increased COL7A1 expression 
in dermal fibroblasts. We identify that this increased C7 production is due to activation of 
the MAPK/ERK and P13K/AKT pathways and subsequent activity of the downstream 
AP-1 transcription factor, and suggest that it is mediated through ROS from exposure 
through fludarabine.  
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RESULTS 
Fludarabine treatment results in increased COL7A1 expression in dermal 
fibroblasts 
Initial results of the clinical trial utilizing HCT to treat RDEB demonstrated a link 
between successful engraftment and an increase in functional C7 deposition at the DEJ 
following transplant (Wagner et al. 2010). However, little was known about the impact of 
the transplant process on endogenous, non-functional C7 expression from the recipient in 
non-hematopoietic cells. Specifically, drugs used in the transplant preparative regimen 
might modulate COL7A1 expression in the transplant recipient, confounding initial 
clinical assessment and potentially impacting the therapeutic benefit of incoming 
functional C7 from the donor cells. Therefore, we examined drugs found in the HCT 
preparative regimen ascertain if any modulated endogenous COL7A1 expression 
independent of functional type VII collagen produced from the graft (Figure 1a). We 
exposed both fibroblasts and keratinocytes to the drugs associated with the HCT regimen, 
including busulfan, cyclophosphamide, cyclosporine, fludarabine and mycophenolate 
(Figure 1b and c). Following 24h exposure to fludarabine, both RDEB and healthy 
dermal fibroblasts showed a significant increase in COL7A1 expression, with COL7A1 
reaching maximum expression levels at 48h following the exposure (Figure 1d and e). 
Furthermore, there was an increase in C7 production in both normal and RDEB 
fibroblasts following exposure to fludarabine (Figure 1f). This led us to examine the 
mechanisms by which fludarabine exposure leads to an increase in COL7A1 expression in 
dermal fibroblasts. 
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P13K/AKT and MAPK/ERK activation following fludarabine exposure 
Fludarabine treatment activates stress pathways, in particular the MAPK/ERK pathway 
(Fernández-Calotti et al. 2006; Maggio et al. 2004). To determine whether fludarabine 
activates MAPK family members in normal and RDEB fibroblasts, we utilized the 
Human Phospho-MAPK Array to investigate the relative activation of each of the MAPK 
members following exposure to fludarabine (R&D Systems, Minneapolis, MN, USA). 
Following 15 minutes of exposure to fludarabine, there was a relative increase in 
phosphorylation of kinases associated with the P13K/AKT pathway (AKT1, AKT2, 
GSK3α/β, HSP27) as well as kinases associated with the MAPK/ERK pathway 
(ERK1/ERK2) (Figure 2a and b).  
 
To confirm that AKT and ERK were activated following exposure to fludarabine, we 
utilized immunoblots with antibodies specific to the phosphorylated forms of AKT and 
ERK. Following 15 minutes of exposure to fludarabine, we saw a relative increase in the 
phosphorylation of AKT (Figure 3a), as well as an increase in the relative 
phosphorylation of ERK1/2 (Figure 3b). This demonstrates that both the P13K/AKT and 
MAPK/ERK pathways are activated following fludarabine exposure. 
 
Fludarabine modulates COL7A1 expression via P13K/AKT and MAPK/ERK 
activity 
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COL7A1 is upregulated in fibroblasts in response to inflammation and UV light (Nakano 
et al. 2001; Nyström et al. 2013b; Verrecchia et al. 2001; Vindevoghel et al. 1998). To 
determine if activation of the MAPK/ERK pathways contributed to COL7A1 
upregulation, we utilized MAPK/ERK pathway inhibitors (PD98059 and U0126) in 
combination with fludarabine. Fibroblasts pre-treated with either MAPK inhibitor and 
sustained treatment with the inhibitor throughout fludarabine exposure showed less of an 
increase in COL7A1 expression in comparison to fibroblasts treated with fludarabine 
alone (Figure 3c-f). We also sought to determine if the P13K/AKT pathway contributed 
to COL7A1 upregulation in a similar fashion. Similarly, fibroblasts pre-treated with an 
AKT pathway inhibitor (LY294002) and treated with the inhibitor throughout fludarabine 
exposure showed less of an increase in COL7A1 expression in comparison to fibroblasts 
treated with fludarabine alone (Figure 3g-h). This demonstrates that fludarabine is 
capable of activating the P13K/AKT and MAPK/ERK pathways, and that an increase in 
COL7A1 upon fludarabine exposure is mediated in part through both P13K/AKT and 
MAPK/ERK activity.  
 
Previous reports have demonstrated that fludarabine treatment results in generation of 
ROS, and that some of fludarabine’s effects may be mediated through ROS (Rosato et al. 
2008; Wu et al. 2002). Specifically, the MAPK/ERK pathway is activated by ROS, and 
the increase in COL7A1 expression in fibroblasts exposed to fludarabine may be a result 
of the MAPK/ERK pathway being activated by ROS (Frank et al. 2000). To determine if 
an increase in COL7A1 expression in fibroblasts exposed to fludarabine is mediated 
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through ROS, we utilized N-acetyl-cysteine (NAC). NAC is a free radical scavenger 
capable of reducing ROS levels in culture (Fernández-Calotti et al. 2006; Nakano et al. 
2001). Upon co-administration of fludarabine and NAC, we saw a reduction in COL7A1 
expression levels in comparison to fibroblasts exposed to fludarabine alone (Figure 4). 
This demonstrates that fludarabine-induced upregulation of COL7A1 in dermal 
fibroblasts may be partly mediated through ROS generation. 
 
Fludarabine modulates COL7A1 expression through AP-1 
The MAPK/ERK and P13K/AKT pathways have a host of downstream transcription 
factors that mediate upregulation of genes following particular stimuli. AP-1, a 
transcription factor typically composed of the canonical FOS/JUN heterodimer, mediates 
transcription of many genes following both P13K/AKT and MAPK/ERK activation 
(Bishnupuri et al. 2006; Frigo et al. 2004; Silvers et al. 2003; Yang et al. 2012; Yu et al. 
2013). Dermal fibroblasts increase production of C7 upon exposure to UVA light, which 
is mediated through the transcription factor AP-1 (Nakano et al. 2001). To determine if 
an increase in COL7A1 expression following fludarabine exposure is mediated through 
AP-1, we utilized an AP-1 inhibitor (SR-11302) in combination with fludarabine. 
Fibroblasts pre-treated with SR-11302 and treated with the inhibitor throughout 
fludarabine exposure showed a smaller increase in COL7A1 expression in comparison to 
fibroblasts treated with fludarabine alone (Figure 5a and b). This demonstrates that an 
increase in COL7A1 expression following fludarabine exposure is mediated, in part, 
through AP-1 activity. These findings highlight a potential mechanism by which 
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fludarabine treatment leads to activation of P13K/AKT and MAPK/ERK, subsequent 
activation of AP-1, and increased COL7A1 expression (Figure 5c). 
 
DISCUSSION 
Since cellular therapies are increasingly used to treat genetic disorders, it is critical to 
understand how the treatment process influences the outcomes and benchmarks of 
success. We demonstrate that fludarabine treatment results in a substantial increase in 
COL7A1 expression in both healthy and RDEB fibroblasts. This increase in COL7A1 
expression is partially mediated through activation of both the P13K/AKT and 
MAPK/ERK pathways and subsequent increase in downstream AP-1 transcriptional 
activity, and is likely mediated through ROS generation. This finding is consistent with 
the various side effects of chemotherapy, specifically the side effects of fludarabine, on 
non-hematopoietic cells (Eissner et al. 2002; Fernández-Calotti et al. 2006). 
 
Cellular responses to injury or stress have been well characterized, including the 
MAPK/ERK and P13K/AKT responses to ROS and DNA damage (Frank et al. 2000; 
Yang et al. 2012). C7 and other extracellular matrix proteins are required for tissue repair 
following injury to the skin, and so it is reasonable that cellular responses to stress or 
DNA damage similar to UV exposure or tissue injury, lead to an increase in C7 (Nyström 
et al. 2013b; Watt and Fujiwara 2011). Furthermore, the tissue-specific response to 
fludarabine in fibroblasts versus keratinocytes is consistent with previous studies 
investigating fibroblast and keratinocyte responses to UV radiation, IL-1β, and TNF-α 
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(Chen et al. 1997; Takeda et al. 2005). While fludarabine influences fibroblasts to 
increase COL7A1 expression, it remains to be seen if there are other side effects in RDEB 
skin due to the preparative regimen. 
 
In using HCT to treat RDEB, it appears that the transplant regimen itself may confound 
initial testing based on COL7A1 expression alone. Testing functional C7 as well as donor 
chimerism may be necessary to determine the efficacy of the transplant. In addition, 
follow-up beyond the period in which the preparative regimen may influence COL7A1 
expression may be necessary to determine whether the newly produced C7 originated 
from the transplanted donor cells or from an increase in C7 expression derived from the 
patient’s cells in response to the conditioning regimen. Based on previous studies using 
fibroblast cellular therapy, it appears that functional C7 is stable at the DEJ junction for 
up to 100 days. Therefore, testing C7 expression and deposition beyond this time point 
may be more informative than testing immediately following transplant (Kern et al. 
2009b). Current and future studies focusing on cellular therapies where preparatory 
regimens or drugs are involved should consider this.  
 
Furthermore, it is unclear as to whether an increase in non-functional C7 production 
would be beneficial, detrimental, or inconsequential in the context of HCT for treatment 
of RDEB. RDEB is a complex disease with a large degree of variation in both severity 
and clinical presentation. Additionally, confounding factors such as genetic modifiers can 
have a profound effect on RDEB phenotype (Küttner et al. 2013; Odorisio et al. 2014). A 
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small overall increase in the amount of C7 produced may reduce the severity of the 
disease for patients with milder forms of RDEB (Tolar et al. 2009; Wagner et al. 2010). 
However, an increase in non-functional C7 deposited at the DEJ might impede incoming 
functional C7 from the HCT graft from depositing. Also, there is some dispute over 
whether truncated forms in C7 in RDEB patients may actually promote tumorigenesis 
through RAS signaling (Ortiz-Urda et al. 2005). If the preparative regimen is determined 
to be detrimental to outcomes, it may be beneficial to use a reduced conditioning 
regimen, or include other types of stem/progenitor cells (Geyer et al. 2015; Perdoni et al. 
2014). 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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Cell culture 
Normal and RDEB human dermal fibroblasts were maintained in Dulbecco’s modified 
Eagle media supplemented with 10% fetal bovine serum, 100 U/ml nonessential amino 
acids, and 0.1 mg/ml each of penicillin and streptomycin (Invitrogen). Normal and RDEB 
keratinocytes were maintained in Epilife medium supplemented with 60 µM calcium, 1% 
Epilife Defined Growth Supplement, and 1% gentamicin/amphotericin solution 
(Invitrogen).  
 
Drugs and Inhibitors 
Drugs from the HCT preparative regimen including busulfan (60 µg/ml, B2635, Sigma-
Aldrich), cyclophosphamide (100 µg/ml, C0768, Sigma-Aldrich), cyclosporine A (10 
µg/ml, 9973, Cell Signaling Technology, Inc.), fludarabine (5 µg/ml, F2773, Sigma-
Aldrich), and mycophenolate (10 µg/ml, M3536, Sigma-Aldrich) were added directly to 
the media. Inhibitors including PD 98059 (5 µM, P215, Sigma-Aldrich), U0126 (10 µM, 
9903, Cell Signaling Technology), LY 294002 (50 µM, L9908, Sigma-Aldrich), and SR 
11302 (10 µM, A8185, Apex Bio) as well as n-acetyl-cysteine (10 mM, A7250, Sigma-
Aldrich) were added alone or 1h prior in combination with fludarabine. All drugs and 
inhibitors were resuspended in dimethyl sulfoxide (D2650, Sigma-Aldrich). 
 
RT-PCR 
RNA was isolated using the RNeasy Plus Mini Kit (QIAGEN). Subsequent first strand 
cDNA synthesis was performed using the SuperScript Vilo cDNA Synthesis Kit 
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(Invitrogen). RT-PCR was performed using Taqman Gene Expression Assays and 
Taqman Universal Master Mix II, no UNG (Invitrogen). RT-PCR was performed on the 
StepOnePlus Real-Time PCR System (Applied Biosystems). The Taqman Gene 
Expression assays used for qRT-PCR experiments on human samples were: 
Hs00164310_m1 (COL7A1) and Hs02758991_g1 (GAPDH) as an endogenous control. 
The Taqman Gene Expression assays used for qRT-PCR experiments on mouse samples 
were: Mm01227938_m1 (COL7A1) and Mm99999915_g1 (GAPDH) as an endogenous 
control. 
 
Immunoblot 
Normal and RDEB fibroblasts were treated with fludarabine prior to cell lysis. Cells were 
lysed in RIPA buffer containing a protease/phosphatase inhibitor cocktail (Cell Signaling 
Technology). Lysates were clarified and measured for protein concentration using a BCA 
protein assay prior to loading. Equal quantities of protein were loaded onto 3-8% tris-
acetate gel. Following electrophoresis, protein was transferred onto a nitrocellulose 
membrane and incubated with primary antibodies overnight. For staining of type VII 
collagen, primary antibodies were either anti-C7 antibody (a kind gift provided by Drs. 
David Woodley and Mei Chen) or anti-β-Actin (A2228, Sigma-Aldrich). For staining of 
AKT/pAKT, antibodies were either anti-Phospho-AKT (9271, Cell Signaling 
Technology) or AKT (pan) (4691, Cell Signaling Technology). For staining of 
ERK/pERK, antibodies were either anti-phospho-p44/42-MAPK (4370, Cell Signaling 
Technology) or anti-p44/42 MAPK (4695, Cell Signaling Technology). The following 
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day, membranes were incubated with goat anti-rabbit HRP-conjugated secondary 
antibody (sc-2005, Santa Cruz Biotechnology). After incubation with secondary 
antibody, blots were developed using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Fischer Scientific) and developed on X-ray film for imaging. 
 
Proteome Profiler Array 
Normal and RDEB dermal fibroblasts were treated with fludarabine for 15 minutes prior 
to cell lysis. Cell lysates were then used with the Human Phospho-MAPK Array 
(ARY002B, R&D Systems). Optical density was analyzed using AlphaImager EC 
software (Alpha Innotech). The average between duplicate spots was then compared 
between untreated and fludarabine-treated blots and graphed in descending order, starting 
with the highest relative average in comparison to untreated control. 
 
Statistics 
All data are presented as mean ± SD of three or more independent biological replicates. 
Student’s T test was used to determine the significance between two groups or between 
an experimental variable and a control. P-values ≤ 0.05 were considered to be statistically 
significant. 
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Figure 1. RDEB Patient exhibits increase in C7 deposition despite engraftment 
failure. (a) Diagram of HCT preparative regimen. Prior to transplant, patients receive 
busulfan, fludarabine, and cyclophosphamide. Following transplant patients are also 
given immunosuppressive drugs including cyclosporine and mycophenolate. Fibroblasts 
(b) and keratinocytes (c) were screened using drugs from the chemotherapy preparative 
regimen. Quantitative RT-PCR analysis of COL7A1 expression relative to GAPDH 
expression following 24h of exposure. The results shown correspond to the mean ± SEM 
of 3 independent experiments. Normal (d) and RDEB (e) dermal fibroblasts were 
exposed to fludarabine and subsequently analyzed for COL7A1 expression. Quantitative 
RT-PCR analysis of COL7A1 expression relative to GAPDH expression following 24, 48, 
or 72h of exposure. The results shown correspond to the mean ± SEM of 3 independent 
experiments. Normal and RDEB dermal fibroblasts (f) were exposed to fludarabine and 
subsequently analyzed for type VII collagen protein expression at 48, 72, and 96h post 
exposure. 10 µg of protein was loaded per well and protein blot was stained for both type 
VII collagen and beta actin as a loading control. *Statistically significant (p<0.05) in 
comparison to untreated cells at matched time points. HCT, hematopoietic stem cell 
transplant; RDEB, recessive dystrophic epidermolysis bullosa; RT-PCR, reverse 
transcriptase PCR. 
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Figure 2. Fludarabine exposure results in activation of the P13K/AKT and 
MAPK/ERK pathways in normal and RDEB fibroblasts. Proteome Profiler (a) arrays 
were used to identify changes in MAPK family activity following exposure to 
fludarabine. Densitometry analysis identifies changes in relative phosphorylation 
between both untreated and fludarabine-treated normal and RDEB fibroblasts. Averages 
between duplicate spots were then compared between untreated and fludarabine-treated 
blots and graphed accordingly (b) RDEB, recessive dystrophic epidermolysis bullosa; 
MAPK, mitogen-activated protein kinases. 
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Figure 3. Fludarabine exposure results in activation of the P13K/AKT and 
MAPK/ERK pathways in normal and RDEB fibroblasts. AKT (a) and ERK (b) 
phosphorylation was analyzed via western blot in normal and RDEB fibroblasts. 
Fibroblasts were incubated with or without fludarabine for 15 minutes prior to cell lysis. 
Western blot was performed and antibodies against total AKT/phospho-AKT or total 
ERK/phospho-ERK were used during Immunoblotting. Inhibition of the MAPK/ERK 
pathway attenuates COL7A1 upregulation following fludarabine exposure. Normal 
fibroblasts (c) or RDEB fibroblasts (d) were initially incubated with an ERK inhibitor 
(PD98095) for 1h prior to being treated with fludarabine and the inhibitor for 24h. 
Quantitative RT-PCR analysis was performed of COL7A1 expression relative to GAPDH 
expression following fludarabine exposure. Inhibition of the MAPK/ERK pathway 
attenuates COL7A1 upregulation following fludarabine exposure. Normal human 
fibroblasts (e) or RDEB fibroblasts (f) were initially incubated with an ERK inhibitor 
(U0126) for 1h prior to being treated with fludarabine and the inhibitor for 24h. 
Quantitative RT-PCR analysis was performed of COL7A1 expression relative to GAPDH 
expression following fludarabine exposure. Inhibition of the AKT pathway attenuates 
COL7A1 upregulation following fludarabine exposure. Normal human fibroblasts (g) or 
RDEB fibroblasts (h) were initially incubated with an AKT inhibitor (LY 294002) for 1h 
prior to being treated with fludarabine and the inhibitor for 24h. Quantitative RT-PCR 
analysis was performed of COL7A1 expression relative to GAPDH expression following 
fludarabine exposure. RDEB, recessive dystrophic epidermolysis bullosa; RT-PCR, 
reverse transcriptase PCR. The results show correspond to the mean ± SEM of 3 
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independent experiments. *Statistically significant (p<0.05) in comparison to untreated 
cells or cells treated with fludarabine and inhibitor.  
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Figure 4. Reactive Oxygen species mediates upregulation of COL7A1 following 
fludarabine exposure. Dermal fibroblasts were initially incubated with N-Acetyl-
Cysteine for 1h prior to being treated with fludarabine and NAC for 24h. Quantitative 
RT-PCR analysis was performed of COL7A1 expression relative to GAPDH expression 
following fludarabine exposure. RDEB, recessive dystrophic epidermolysis bullosa; RT-
PCR, reverse transcriptase PCR. The results show correspond to the mean ± SEM of 3 
independent experiments. *Statistically significant (p<0.05) in comparison to untreated 
cells or cells treated with fludarabine and NAC.  
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Figure 5: Inhibition of the AP-1 attenuates COL7A1 upregulation following 
fludarabine exposure. Normal dermal fibroblasts (a) or RDEB fibroblasts (b) were 
initially incubated with an AP-1 inhibitor (SR 11302) for 1h prior to being treated with 
fludarabine for 24h. Quantitative RT-PCR analysis was performed of COL7A1 
expression relative to GAPDH expression following fludarabine exposure. A Schematic 
Diagram illustrating the proposed model by which fludarabine treatment leads to 
upregulated C7 (c) Fludarabine treatment leads to activation of both the P13K/AKT and 
MAPK/ERK pathways. Subsequently, AKT and ERK activity leads to downstream 
activation of the transcription factor, AP-1. AP-1 then binds to the AP-1 transcriptional 
response element (AP1-TRE) in the COL7A1 promoter, which leads to an increased 
transcription of COL7A1. RDEB, recessive dystrophic epidermolysis bullosa; RT-PCR, 
reverse transcriptase PCR. The results show correspond to the mean ± SEM of 3 
independent experiments. *Statistically significant (p<0.05) in comparison to untreated 
cells or cells treated with fludarabine and inhibitor.  
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Chapter 4: Conclusions and Future Directions 
Recessive Dystrophic Epidermolysis Bullosa is a complicated disorder that 
requires a thorough understanding of the underlying mechanisms that drive the 
pathology, an aggressive approach to fix the underlying cause, and a methodical analysis 
of the efficacy of those therapeutic approaches. This work seeks to compliment the 
ongoing effort to address the underlying cause by identifying a driver of RDEB fibrosis 
and characterizing the influence of fludarabine on COL7A1 expression in the context of 
HCT. In regards to the influence of miR-29 on fibrosis in the context of RDEB, future 
studies should seek to identify all of the genes influenced by miR-29 regulation in the 
context of RDEB and targeting the miR-29 regulatory network, through mimics or target 
protectors, to halt the progression of fibrosis and alleviate the incidence of 
pseudosyndactyly in RDEB patients. The effects of fludarabine on COL7A1 expression in 
the context of RDEB should guide current analysis of HCT and help influence future 
studies on the use of HCT to treat other genetic diseases. 
 The use of miR-29 mimics to treat fibrosis has been effective in the context of 
other settings, including idiopathic pulmonary fibrosis.  While this approach may be 
useful for treating RDEB, a particular and unwanted side effect may be to reduce type 
VII collagen production as well. Future studies should include the use of target protectors 
or similar approaches to simultaneously separate the influence of miR-29 on COL7A1 
while utilizing miR-29s ability to reduce fibrosis.  This approach may also be useful in 
the context of drugs that reduce TGF-β activity, including the recently used drug Losartan 
to ameliorate RDEB pathology. Furthermore, miR-29 may be a useful biomarker capable 
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of indicating the overall health and stability of RDEB skin. Measuring miR-29 levels 
following therapeutic approaches for treating RDEB or drug treatments that reduce TGF-
β activity may be informative of the drug treatment or therapy’s effectiveness. 
 While the effects of fludarabine proved meaningful in revealing a previously 
unknown mechanism of COL7A1 regulation, fludarabine causes a myriad of side effects 
the most severe of which are life threatening, and for that reason should be avoided for 
sole purpose of promoting upregulation of COL7A1. These studies were however 
meaningful in providing insight into the time frame and duration of upregulation of 
COL7A1 expression in HCT recipient cells following transplant, and should provide 
guidance in the analysis of HCT’s efficacy. Based on our analysis of the influence of 
fludarabine on COL7A1 expression in RDEB cells, we posit that fludarabine treatment 
likely results in a short term increase in mutated COL7A1 in RDEB patients, and that 
increase is temporary.  The mutated C7 produced is likely only present for one month 
post fludarabine exposure. Therefore, any analysis of COL7A1 expression in the context 
of HCT prior to one month post-transplant may require an approach that is capable of 
differentiating between C7 produced by the graft and C7 produced by the host that is 
temporarily upregulated due to fludarabine. 
 This work, along with other ongoing efforts to further understand pathology of 
RDEB and potential therapeutic approaches to treating it, will hopefully result in 
meaningful and effective treatment of RDEB. While RDEB is a complicated and 
challenging disorder to treat, there have been recent successes and strides that make a 
future cure seem plausible.  While it is unclear as to what approach or avenue will be the 
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most effective, a combinatorial effort to both treat and understand RDEB can only help 
move the field forward and accelerate the time frame of when a future cure will become 
realized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
References 
Alexeev V, Uitto J, Igoucheva O. Gene expression signatures of mouse bone marrow-
derived mesenchymal stem cells in the cutaneous environment and therapeutic 
implications for blistering skin disorder. Cytotherapy. 2011;13(1):30–45  
Bhattacharyya S, Tamaki Z, Wang W, Hinchcliff M, Hoover P, Getsios S, et al. 
FibronectinEDA Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor 
Signaling. Sci. Transl. Med. 2014;6(232):232ra50-232ra50  
Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK. Reg IV 
Activates the Epidermal Growth Factor Receptor/Akt/AP-1 Signaling Pathway in Colon 
Adenocarcinomas. Gastroenterology. 2006;130(1):137–49  
Bonin M, Pursche S, Bergeman T, Leopold T, Illmer T, Ehninger G, et al. F-ara-A 
pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and 
busulfan. Bone Marrow Transplant. 2007;39(4):201–6  
Bornhäuser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, et al. 
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic 
hematopoietic stem cells. Blood. 2003;102(3):820–6  
Bremer J, Bornert O, Nyström A, Gostynski A, Jonkman MF, Aartsma-Rus A, et al. 
Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach 
for Recessive Dystrophic Epidermolysis Bullosa. Mol. Ther. - Nucleic Acids. 
2016;5(10):e379  
Calonge MJ, Seoane J, Massagué J. Opposite Smad and chicken ovalbumin upstream 
promoter transcription factor inputs in the regulation of the collagen VII gene promoter 
by transforming growth factor-beta. J. Biol. Chem. 2004;279(22):23759–65  
Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188(4):773–
82  
Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, et al. Restoration of 
type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat. 
Genet. 2002;32(4):670–5  
Chen M, Keene DR, Costa FK, Tahk SH, Woodley DT. The Carboxyl Terminus of Type 
VII Collagen Mediates Antiparallel Dimer Formation and Constitutes a New Antigenic 
Epitope for Epidermolysis Bullosa Acquisita Autoantibodies. J. Biol. Chem. 
2001;276(24):21649–55  
Chen M, Petersen MJ, Li HL, Cai XY, O’Toole EA, Woodley DT. Ultraviolet A 
irradiation upregulates type VII collagen expression in human dermal fibroblasts. J. 
79 
 
Invest. Dermatol. 1997;108(2):125–8  
Chen H-Y, Zhong X, Huang XR, Meng X-M, You Y, Chung AC, et al. MicroRNA-29b 
Inhibits Diabetic Nephropathy in db/db Mice. Mol. Ther. 2014;95(3):231–5  
Cheng J, Wang Y, Wang D, Wu Y. Identification of collagen 1 as a post-transcriptional 
target of miR-29b in skin fibroblasts: therapeutic implication for scar reduction. Am. J. 
Med. Sci. 2013;346(2):98–103  
Chernov A V, Strongin AY. Epigenetic regulation of matrix metalloproteinases and their 
collagen substrates in cancer. Biomol. Concepts. 2011;2(3):135–47  
Christiano A, Anhalt G, Gibbons S, Bauer EA, Uitto J. Premature Termination Codons in 
the Type VII Collagen Gene (COL7A1) Underlie Severe, Mutilating Recessive 
Dystrophic Epidermolysis Bullosa. Genomics. 1994a;21(1):160–8  
Christiano A, Hoffman GG, Chung-Honet LC, Lee S, Cheng W, Uitto J, et al. Structural 
Organization of the Human Type VII Collagen Gene (COL7A1), Composed of More 
Exons Than Any Previously Characterized Gene. Genomics. 1994b;21(1):169–79  
Cogan J, Weinstein J, Wang X, Hou Y, Martin S, South AP, et al. Aminoglycosides 
Restore Full-length Type VII Collagen by Overcoming Premature Termination Codons: 
Therapeutic Implications for Dystrophic Epidermolysis Bullosa. Mol. Ther. 
2014;22(10):1741–52  
Conget P, Rodriguez F, Kramer S, Allers C, Simon V, Palisson F, et al. Replenishment of 
type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal 
administration of allogeneic mesenchymal stromal cells in two patients with recessive 
dystrophic epidermolysis bullosa. Cytotherapy. 2010;12(3):429–31  
Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, et al. miR-29 is a major regulator 
of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 
2011;45(2):287–94  
Cutlar L, Gao Y, Aied A, Greiser U, Murauer EM, Zhou D, et al. A knot polymer 
mediated non-viral gene transfection for skin cells. Biomater. Sci. The Royal Society of 
Chemistry; 2016;4(1):92–5  
Dang N, Murrell DF. Mutation analysis and characterization of COL7A1 mutations in 
dystrophic epidermolysis bullosa. Exp. Dermatol. 2008;17(7):553–68  
Driskell RR, Lichtenberger BM, Hoste E, Kretzschmar K, Simons BD, Charalambous M, 
et al. Distinct fibroblast lineages determine dermal architecture in skin development and 
repair. Nature. Nature Publishing Group; 2013;504(7479):277–81  
Dunnill MG, McGrath JA, Richards AJ, Christiano AM, Uitto J, Pope FM, et al. 
80 
 
Clinicopathological correlations of compound heterozygous COL7A1 mutations in 
recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 1996;107(2):171–7  
Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S, et al. Fludarabine 
induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: 
Protective effect of defibrotide. Blood. 2002;100(1):334–40  
Fernández-Calotti P, Gamberale R, Costas M, Sánchez Avalos J, Geffner J, Giordano M. 
Fludarabine induces pro-inflammatory activation of human monocytic cells through a 
MAPK/ERK pathway. Int. Immunopharmacol. 2006;6(5):715–23  
Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, et al. 
Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in 
Experimental Autoimmune Type 1 Diabetes. J. Immunol. BioMed Central; 
2009;183(2):993–1004  
Florin L, Hummerich L, Dittrich BT, Kokocinski F, Wrobel G, Gack S, et al. 
Identification of novel AP-1 target genes in fibroblasts regulated during cutaneous wound 
healing. Oncogene. 2004;23(42):7005–17  
Frank GD, Eguchi S, Yamakawa T, Tanaka S, Inagami T, Motley ED. Involvement of 
Reactive Oxygen Species in the Activation of Tyrosine Kinase and Extracellular Signal-
Regulated Kinase by Angiotensin II 1. Endocrinology. Oxford University Press; 
2000;141(9):3120–6  
Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved 
targets of microRNAs. 2009;92–105  
Frigo DE, Tang Y, Beckman BS, Scandurro AB, Alam J, Burow ME, et al. Mechanism 
of Ap-1-mediated gene expression by select organochlorines through the p38 MAPK 
pathway. Carcinogenesis. 2004;25(2):249–61  
Fritsch A, Loeckermann S, Kern JS, Braun A, Bösl MR, Bley TA, et al. A hypomorphic 
mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and 
response to fibroblast therapy. J. Clin. Invest. American Society for Clinical 
Investigation; 2008;118(5):1669–79  
Gache Y, Baldeschi C, Del Rio M, Gagnoux-Palacios L, larcher F, Lacour J-P, et al. 
Construction of Skin Equivalents for Gene Therapy of Recessive Dystrophic 
Epidermolysis Bullosa. Hum. Gene Ther.  Mary Ann Liebert, Inc.  2 Madison Avenue 
Larchmont, NY 10538 USA  ; 2004;15(10):921–33  
Gaj T, Gersbach C a, Iii CFB, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based 
methods for genome engineering. Trends Biotechnol. Elsevier Ltd; 2013;31(7):397–405  
Gardella R, Barlati S, Zoppi N, Tadini G, Colombi M. A -96C-->T mutation in the 
81 
 
promoter of the collagen type VII gene (COL7A1) abolishing transcription in a patient 
affected by recessive dystrophic epidermolysis bullosa. Hum. Mutat. John Wiley & Sons, 
Inc.; 2000;16(3):275  
Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CEA, Callegari E, et al. MicroRNA-29b 
induces global DNA hypomethylation and tumor suppressor gene reexpression in acute 
myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 
American Society of Hematology; 2009;113(25):6411–8  
Georgiadis C, Syed F, Petrova A, Abdul-Wahab A, Lwin SM, Farzaneh F, et al. 
Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore 
Anchoring Fibrils in RDEB. J. Invest. Dermatol. 2016;136(1):284–92  
Geyer MB, Radhakrishnan K, Giller R, Umegaki N, Harel S, Kiuru M, et al. Reduced 
Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for 
Recessive Dystrophic Epidermolysis Bullosa. J. Pediatr. 2015;167(3):765–769.e1  
Goto M, Sawamura D, Nishie W, Sakai K, McMillan JR, Akiyama M, et al. Targeted 
Skipping of a Single Exon Harboring a Premature Termination Codon Mutation: 
Implications and Potential for Gene Correction Therapy for Selective Dystrophic 
Epidermolysis Bullosa Patients. J. Invest. Dermatol. 2006;126(12):2614–20  
Guerra L, Odorisio T, Zambruno G, Castiglia D. Stromal microenvironment in type VII 
collagen-deficient skin: The ground for squamous cell carcinoma development. Matrix 
Biol. 2017;  
Hayashi R, Ishikawa Y, Ito M, Kageyama T, Takashiba K, Fujioka T, et al. Generation of 
corneal epithelial cells from induced pluripotent stem cells derived from human dermal 
fibroblast and corneal limbal epithelium. PLoS One. 2012;7(9):e45435  
Hou Y, Guey LT, Wu T, Gao R, Cogan J, Wang X, et al. Intravenously Administered 
Recombinant Human Type VII Collagen Derived from Chinese Hamster Ovary Cells 
Reverses the Disease Phenotype in Recessive Dystrophic Epidermolysis Bullosa Mice. J. 
Invest. Dermatol. 2015;135(12):3060–7  
Iinuma S, Aikawa E, Tamai K, Fujita R, Kikuchi Y, Chino T, et al. Transplanted Bone 
Marrow–Derived Circulating PDGFRα + Cells Restore Type VII Collagen in Recessive 
Dystrophic Epidermolysis Bullosa Mouse Skin Graft. J. Immunol. 2015;194(4):1996–
2003  
Jacków J, Titeux M, Portier S, Charbonnier S, Ganier C, Gaucher S, et al. Gene-
Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a 
Self-Inactivating COL7A1 Retroviral Vector. J. Invest. Dermatol. 2016;136(7):1346–54  
Järvikallio A, Pulkkinen L, Uitto J. Molecular basis of dystrophic epidermolysis bullosa: 
mutations in the type VII collagen gene (COL7A1). Hum. Mutat. Wiley Subscription 
82 
 
Services, Inc., A Wiley Company; 1997;10(5):338–47  
Jia L-F, Huang Y-P, Zheng Y-F, Lyu M-Y, Wei S-B, Meng Z, et al. miR-29b suppresses 
proliferation, migration, and invasion of tongue squamous cell carcinoma through PTEN–
AKT signaling pathway by targeting Sp1. Oral Oncol. Elsevier Ltd; 2014;50(11):1062–
71  
Jiang H, Su Z, Datta S, Guarini L, Waxman S, Fisher P. Fludarabine phosphate 
selectively inhibits growth and modifies the antigenic phenotype of human glioblastoma-
multiforme cells expressing a multidrug resistance phenotype. Int. J. Oncol. 
1992;1(2):227–39  
Jiang H, Zhang G, Wu J-H, Jiang C-P. Diverse roles of miR-29 in cancer (Review). 
Oncol. Rep. Spandidos Publications; 2014;31(4):1509–16  
Jiang L, Zhou Y, Xiong M, Fang L, Wen P, Cao H, et al. Sp1 mediates microRNA-29c-
regulated type I collagen production in renal tubular epithelial cells. Exp. Cell Res. 
Elsevier; 2013;319(14):2254–65  
Kern JS, Grüninger G, Imsak R, Müller ML, Schumann H, Kiritsi D, et al. Forty-two 
novel COL7A1 mutations and the role of a frequent single nucleotide polymorphism in 
the MMP1 promoter in modulation of disease severity in a large European dystrophic 
epidermolysis bullosa cohort. Br. J. Dermatol. 2009a;161(5):1089–97  
Kern JS, Loeckermann S, Fritsch A, Hausser I, Roth W, Magin TM, et al. Mechanisms of 
fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII 
favors long-term skin integrity. Mol. Ther. The American Society of Gene & Cell 
Therapy; 2009b;17(9):1605–15  
Kirkorian AY, Weitz NA, Tlougan B, Morel KD. Evaluation of Wound Care Options in 
Patients with Recessive Dystrophic Epidermolysis Bullosa: A Costly Necessity. Pediatr. 
Dermatol. 2013;31(1):33–7  
Kon A, Takeda H, Ito N, Hanada K, Takagaki K. Tissue-specific downregulation of type 
VII collagen gene (COL7A1) transcription in cultured epidermal keratinocytes by 
ultraviolet A radiation (UVA) and UVA-inducible cytokines, with special reference to 
cutaneous photoaging. J. Dermatological Sci. Suppl. 2005;1(2):S29–35  
Kon A, Vindevoghel L, Kouba DJ, Fujimura Y, Uitto J, Mauviel A. Cooperation between 
SMAD and NF-κB in growth factor regulated type VII collagen gene expression. 
Oncogene. Nature Publishing Group; 1999;18(10):1837–44  
Küttner V, Mack C, Rigbolt KTG, Kern JS, Schilling O, Busch H, et al. Global 
remodelling of cellular microenvironment due to loss of collagen VII. Mol. Syst. Biol. 
2013;9(657):657  
83 
 
Latella MC, Cocchiarella F, De Rosa L, Turchiano G, Gonçalves MAFV, Larcher F, et 
al. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated 
Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes. J. 
Invest. Dermatol. 2017;137(4):836–44  
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, 
indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20  
Li N, Cui J, Duan X, Chen H, Fan F. Suppression of type I collagen expression by miR-
29b via PI3K, Akt, and Sp1 pathway in human Tenon’s fibroblasts. Investig. Ophthalmol. 
Vis. Sci. 2012;53(3):1670–8  
Li J, Du S, Sheng X, Liu J, Cen B, Huang F, et al. MicroRNA-29b Inhibits Endometrial 
Fibrosis by Regulating the Sp1-TGF- 1/Smad-CTGF Axis in a Rat Model. Reprod. Sci. 
2015a;:1–9  
Li D, Li X, Wang A, Meisgen F, Pivarcsi A, Sonkoly E, et al. MicroRNA-31 Promotes 
Skin Wound Healing by Enhancing Keratinocyte Proliferation and Migration. J. Invest. 
Dermatol. 2015b;135(6):1676–85  
Liu P, Deng Z, Han S, Liu T, Wen N, Lu W, et al. Tissue-engineered skin containing 
mesenchymal stem cells improves burn wounds. Artif. Organs. 2008;32(12):925–31  
Liu Y, Taylor NE, Lu L, Usa K, Cowley AW, Ferreri NR, et al. Renal medullary 
MicroRNAs in dahl salt-sensitive rats: MiR-29b regulates several collagens and related 
genes. Hypertension. 2010a;55(4):974–82  
Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, et al. Sp1/NFκB/HDAC/miR-
29b Regulatory Network in KIT-Driven Myeloid Leukemia. Cancer Cell. Elsevier Ltd; 
2010b;17(4):333–47  
Lu L, Xue X, Lan J, Gao Y, Xiong Z, Zhang H, et al. MicroRNA-29a upregulates MMP2 
in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomed. 
Pharmacother. 2014;68(1):13–9  
Luna C, Li G, Qiu J, Epstein DL, Gonzalez P. Role of miR-29b on the regulation of the 
extracellular matrix in human trabecular meshwork cells under chronic oxidative stress. 
Mol. Vis. 2009;15(November):2488–97  
Mack MR, Wendelschafer-Crabb G, McAdams BD, Hordinsky MK, Kennedy WR, Tolar 
J. Peripheral Neuro-Immune Pathology in Recessive Dystrophic Epidermolysis Bullosa. 
J. Invest. Dermatol. Nature Publishing Group; 2014;135(4):1193–7  
Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, et al. The Histone 
Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce 
Apoptosis in Human Leukemia Cells. Cancer Res. 2004;64(7):2590–600  
84 
 
Mittapalli VR, Madl J, Lo ffek S, Kiritsi D, Kern JS, Ro mer W, et al. Injury-Driven 
Stiffening of the Dermis Expedites Skin Carcinoma Progression. Cancer Res. 
2016;76(4):940–51  
Moon ES, Jung ST, Kim MS. Surgical treatment of pseudosyndactyly of children with 
epidermolysis bullosa: a case report. Hand Surg. An Int. J. Devoted To Hand Up. Limb 
Surg. Relat. Res. J. Asia-Pacific Fed. Soc. Surg. Hand. 2007;12(3):143–7  
Morita S, Horii T, Kimura M, Ochiya T, Tajima S, Hatada I. miR-29 represses the 
activities of DNA methyltransferases and DNA demethylases. Int. J. Mol. Sci. 
Multidisciplinary Digital Publishing Institute  (MDPI); 2013;14(7):14647–58  
Murauer EM, Gache Y, Gratz IK, Klausegger A, Muss W, Gruber C, et al. Functional 
correction of type VII collagen expression in dystrophic epidermolysis bullosa. J. Invest. 
Dermatol. Nature Publishing Group; 2011;131(1):74–83  
Nagy N, Almaani N, Tanaka A, Lai-Cheong JE, Techanukul T, Mellerio JE, et al. HB-
EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism 
underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa. J. 
Invest. Dermatol. The Society for Investigative Dermatology, Inc; 2011;131(8):1771–4  
Nakano H, Gasparro FP, Uitto J. UVA-340 as energy source, mimicking natural sunlight, 
activates the transcription factor AP-1 in cultured fibroblasts: evidence for involvement 
of protein kinase-C. Photochem. Photobiol. 2001;74(2):274–82  
Nakashima Y, Kariya Y, Yasuda C, Miyazaki K. Regulation of Cell Adhesion and Type 
VII Collagen Binding by the  3 Chain Short Arm of Laminin-5: Effect of Its Proteolytic 
Cleavage. J. Biochem. Oxford University Press; 2005;138(5):539–52  
Ng Y-Z, Pourreyron C, Salas-Alanis JC, Dayal JHS, Cepeda-Valdes R, Yan W, et al. 
Fibroblast-Derived Dermal Matrix Drives Development of Aggressive Cutaneous 
Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa. 
Cancer Res. 2012;72(14):3522–34  
Nishioka C, Ikezoe T, Togitani K, Yokoyama A. Fludarabine induces growth arrest and 
apoptosis of cytokine- or alloantigen-stimulated peripheral blood mononuclear cells, and 
decreases production of Th1 cytokines via inhibition of nuclear factor kappaB. Bone 
Marrow Transplant. Nature Publishing Group; 2008;41(3):303–9  
Nyström A, Bruckner-Tuderman L, Kern JS. Cell- and protein-based therapy approaches 
for epidermolysis bullosa. Methods Mol. Biol. 2013a;961:425–40  
Nyström A, Thriene K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, et al. Losartan 
ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. 
EMBO Mol Med. 2015;7:1211–28  
85 
 
Nyström A, Velati D, Mittapalli VR, Fritsch A, Kern JS, Bruckner-Tuderman L. 
Collagen VII plays a dual role in wound healing. J. Clin. Invest. 2013b;123(8):3498–509  
Odorisio T, di Salvio M, Orecchia A, di Zenzo G, Piccinni E, Cianfarani F, et al. 
Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype 
highlight the role of TGF-β signalling in modifying disease severity. Hum. Mol. Genet. 
2014;23(15):3907–22  
Vanden Oever M, Muldoon D, Mathews W, McElmurry R, Tolar J. miR-29 Regulates 
Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa. J. Invest. Dermatol. 
2016;136(10):2013–21  
Ortiz-Urda S, Garcia J, Green CL, Chen L, Lin Q, Veitch DP, et al. Type VII collagen is 
required for Ras-driven human epidermal tumorigenesis. Science. 2005;307(5716):1773–
6  
Osborn MMJ, Starker CCG, McElroy AAN, Webber BR, Riddle MJ, Xia L, et al. 
TALEN-based Gene Correction for Epidermolysis Bullosa. Mol. Ther. 2013;21(6):1–9  
Oshimori N, Oristian D, Oshimori N, Oristian D, Fuchs E. TGF- b Promotes 
Heterogeneity and Drug Resistance in Squamous Cell Carcinoma Article TGF- b 
Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma. Cell. 
Elsevier Inc.; 2015;160(5):963–76  
Parker MW, Rossi D, Peterson M, Smith K, Sikstrom̈ K, White ES, et al. Fibrotic 
extracellular matrix activates a profibrotic positive feedback loop. J. Clin. Invest. 
2014;124(4):1622–35  
Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and 
inflammation. Nat. Rev. Immunol. 2014;14(5):289–301  
Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, et al. p63 
identifies keratinocyte stem cells. Proc. Natl. Acad. Sci. U. S. A. National Academy of 
Sciences; 2001;98(6):3156–61  
Perdoni C, McGrath JA, Tolar J. Preconditioning of mesenchymal stem cells for 
improved transplantation efficacy in recessive dystrophic epidermolysis bullosa. Stem 
Cell Res. Ther. 2014;5(6):121  
Petrof G, Martinez-Queipo M, Mellerio JE, Kemp P, McGrath JA. Fibroblast cell therapy 
enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of 
a randomized, vehicle-controlled trial. Br. J. Dermatol. 2013;169(5):1025–33  
Phimister EG, Tolar J, Wagner JE. A Biologic Velcro Patch. N. Engl. J. Med. 
2015;372(4):382–4  
86 
 
Pourreyron C, Cox G, Mao X, Volz A, Baksh N, Wong T, et al. Patients with recessive 
dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type 
VII collagen expression. J. Invest. Dermatol. 2007;127(10):2438–44  
Qin W, Chung ACK, Huang XR, Meng X-M, Hui DSC, Yu C-M, et al. TGF-β/Smad3 
signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 
2011;22(8):1462–74  
Reimer J, Bien S, Ameling S, Hammer E, Völker U, Hempel G, et al. Antineoplastic 
agent busulfan regulates a network of genes related to coagulation and fibrinolysis. Eur. 
J. Clin. Pharmacol. 2012;68(6):923–35  
Remington J, Wang X, Hou Y, Zhou H, Burnett J, Muirhead T, et al. Injection of 
recombinant human type VII collagen corrects the disease phenotype in a murine model 
of dystrophic epidermolysis bullosa. Mol. Ther. 2009;17(1):26–33  
Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of 
TALENs for high-throughput genome editing. Nat. Biotechnol. Nature Publishing Group, 
a division of Macmillan Publishers Limited. All Rights Reserved.; 2012;30(5):460–5  
Richer BC, Seeger K. The hinge region of type VII collagen is intrinsically disordered. 
Matrix Biol. 2014;36:77–83  
van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. 
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in 
cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A. 2008;105(35):13027–32  
Rosato RR, Almenara J a, Maggio SC, Coe S, Atadja P, Dent P, et al. Role of histone 
deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-
824/fludarabine antileukemic interactions. Mol. Cancer Ther. 2008;7(10):3285–97  
Saito K, Chen M, Bard F, Chen S, Zhou H, Woodley D, et al. TANGO1 Facilitates Cargo 
Loading at Endoplasmic Reticulum Exit Sites. Cell. 2009;136(5):891–902  
Sasaki M, Abe R, Fujita Y, Ando S, Inokuma D, Shimizu H. Mesenchymal Stem Cells 
Are Recruited into Wounded Skin and Contribute to Wound Repair by 
Transdifferentiation into Multiple Skin Cell Type. J. Immunol. 2008;180(4):2581–7  
Sebastiano V, Zhen HH, Haddad B, Derafshi BH, Bashkirova E, Melo SP, et al. Human 
COL7A1-corrected induced pluripotent stem cells for the treatment of recessive 
dystrophic epidermolysis bullosa. Sci. Transl. Med. NIH Public Access; 
2014;6(264):264ra163  
Senoo M, Pinto F, Crum CP, McKeon F. p63 Is essential for the proliferative potential of 
stem cells in stratified epithelia. Cell. 2007;129(3):523–36  
87 
 
Silvers AL, Bachelor M a, Bowden GT. The role of JNK and p38 MAPK activities in 
UVA-induced signaling pathways leading to AP-1 activation and c-Fos expression. 
Neoplasia. 2003;5(4):319–29  
Simpson CL, Patel DM, Green KJ. Deconstructing the skin: cytoarchitectural 
determinants of epidermal morphogenesis. Nat. Rev. Mol. Cell Biol. Nature Publishing 
Group; 2011;12(9):565–80  
Siprashvili Z, Nguyen NT, Bezchinsky MY, Marinkovich MP, Lane AT, Khavari PA. 
Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue. 
Hum. Gene Ther. Mary Ann Liebert, Inc.  140 Huguenot Street, 3rd Floor New Rochelle, 
NY 10801 USA; 2010;21(10):1299–310  
Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, et al. Safety and 
Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in 
Patients With Recessive Dystrophic Epidermolysis Bullosa. JAMA. 2016;316(17):1808  
Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, et al. Mithramycin is 
a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and 
neurodegeneration. J. Neurosci. 2011;31(18):6858–70  
Takeda H, Kon A, Ito N, Sawamura D, Takagaki K, Hashimoto I, et al. Keratinocyte-
specific modulation of type VII collagen gene expression by pro-inflammatory cytokines 
(tumor necrosis factor-alpha and interleukin-1beta). Exp. Dermatol. 2005;14(4):289–94  
Tamai K, Yamazaki T, Chino T, Ishii M, Otsuru S, Kikuchi Y, et al. PDGFRalpha-
positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to 
regenerate injured epithelia. Proc. Natl. Acad. Sci. U. S. A. 2011;108(16):6609–14  
Titeux M, Pendaries V, Zanta-Boussif M a, Décha A, Pironon N, Tonasso L, et al. SIN 
retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy 
of recessive dystrophic epidermolysis bullosa. Mol. Ther. Nature Publishing Group; 
2010;18(8):1509–18  
Tockner B, Kocher T, Hainzl S, Reichelt J, Bauer JW, Koller U, et al. Construction and 
validation of an RNA trans-splicing molecule suitable to repair a large number of 
COL7A1 mutations. Gene Ther. Nature Publishing Group; 2016;23(11):775–84  
Tolar J, Ishida-Yamamoto A, Riddle M, McElmurry RT, Osborn M, Xia L, et al. 
Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood. 
2009;113(5):1167–74  
Tolar J, McGrath JA, Xia L, Riddle MJ, Lees CJ, Eide C, et al. Patient-Specific Naturally 
Gene-Reverted Induced Pluripotent Stem Cells in Recessive Dystrophic Epidermolysis 
Bullosa. J. Invest. Dermatol. The Society for Investigative Dermatology, Inc; 
2013;134(5):1246–54  
88 
 
Tolar J, Xia L, Riddle MJ, Lees CJ, Eide CR, Mcelmurry RT, et al. Induced pluripotent 
stem cells from individuals with recessive dystrophic epidermolysis bullosa. J. Invest. 
Dermatol. Nature Publishing Group; 2011;131(4):848–56  
Tsukada A, Fujimura T, Furudate S, Kambayashi Y, Numata Y, Haga T, et al. Cutaneous 
Squamous Cell Carcinoma Developing from Recessive Dystrophic Epidermolysis 
Bullosa: A Case Report and an Immunohistochemical Study. Case Rep. Dermatol. 
2012;4(3):197–201  
Turczynski S, Titeux M, Tonasso L, Décha A, Ishida-Yamamoto A, Hovnanian A. 
Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril 
Formation in an In Vivo RDEB Model. J. Invest. Dermatol. 2016;136(12):2387–95  
Varki R, Sadowski S, Uitto J, Pfendner E. Epidermolysis bullosa. II. Type VII collagen 
mutations and phenotype-genotype correlations in the dystrophic subtypes. J. Med. 
Genet. 2006;44(3):181–92  
Venugopal SS, Yan W, Frew JW, Cohn HI, Rhodes LM, Tran K, et al. A phase II 
randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive 
dystrophic epidermolysis bullosa. J. Am. Acad. Dermatol. 2013;69(6):898–908.e7  
Verrecchia F, Vindevoghel L, Lechleider RJ, Uitto J, Roberts  a B, Mauviel  a. 
Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-
specific manner. Oncogene. 2001;20(26):3332–40  
Vindevoghel L, Chung KY, Davis A, Kouba D, Kivirikko S, Alder H, et al. A GT-rich 
sequence binding the transcription factor Sp1 is crucial for high expression of the human 
type VII collagen gene (COL7A1) in fibroblasts and keratinocytes. J. Biol. Chem. 
1997;272(15):10196–204  
Vindevoghel L, Lechleider RJ, Kon  a, de Caestecker MP, Uitto J, Roberts  a B, et al. 
SMAD3/4-dependent transcriptional activation of the human type VII collagen gene 
(COL7A1) promoter by transforming growth factor beta. Proc. Natl. Acad. Sci. U. S. A. 
1998;95(25):14769–74  
Wagner JE, Ishida-Yamamoto A, Mcgrath J a, Hordinsky M, Keene DR, Woodley DT, et 
al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N. Engl. 
J. Med. 2010;363(7):629–39  
Wang X, Ghasri P, Amir M, Hwang B, Hou Y, Khalili M, et al. Topical application of 
recombinant type VII collagen incorporates into the dermal-epidermal junction and 
promotes wound closure. Mol. Ther. 2013;21(7):1335–44  
Watt FM, Fujiwara H. Cell-extracellular matrix interactions in normal and diseased skin. 
Cold Spring Harb. Perspect. Biol. 2011;3(4):1–14  
89 
 
Webber BR, Osborn MJ, McElroy AN, Twaroski K, Lonetree C, DeFeo AP, et al. 
CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. 
npj Regen. Med. Nature Publishing Group; 2016;1(1):16014  
Werner S, Krieg T, Smola H. Keratinocyte-fibroblast interactions in wound healing. J. 
Invest. Dermatol. 2007;127(5):998–1008  
Williams SE, Beronja S, Pasolli HA, Fuchs E. Asymmetric cell divisions promote Notch-
dependent epidermal differentiation. Nature. NIH Public Access; 2011;470(7334):353–8  
Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJC, Pacy J, et al. Potential 
of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J. Invest. 
Dermatol. 2008;128(9):2179–89  
Woodley DT, Wang X, Amir M, Hwang B, Remington J, Hou Y, et al. Intravenously 
Injected Recombinant Human Type VII Collagen Homes to Skin Wounds and Restores 
Skin Integrity of Dystrophic Epidermolysis Bullosa. J. Invest. Dermatol. Nature 
Publishing Group; 2013;133(January):1–4  
Wu H-M, Chi K-H, Lin W-W. Proteasome inhibitors stimulate activator protein-1 
pathway via reactive oxygen species production. FEBS Lett. 2002;526(1–3):101–5  
Wu W, Lu Z, Li F, Wang W, Qian N, Duan J, et al. Efficient in vivo gene editing using 
ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse 
model. Proc. Natl. Acad. Sci. U. S. A. National Academy of Sciences; 
2017;114(7):1660–5  
Yang T, Liang Y, Lin Q, Liu J, Luo F, Li X, et al. MiR-29 mediates TGFβ1-induced 
extracellular matrix synthesis through activation of PI3K-AKT pathway in human lung 
fibroblasts. J. Cell. Biochem. 2013;114(6):1336–42  
Yang C-M, Lin C-C, Lee I-T, Lin Y-H, Yang CM, Chen W-J, et al. Japanese encephalitis 
virus induces matrix metalloproteinase-9 expression via a ROS/c-
Src/PDGFR/PI3K/Akt/MAPKs-dependent AP-1 pathway in rat brain astrocytes. J. 
Neuroinflammation. 2012;9(1):517  
Yang X, Wang J, Guo SL, Fan KJ, Li J, Wang YL, et al. miR-21 promotes keratinocyte 
migration and re-epithelialization during wound healing. Int. J. Biol. Sci. 2011;7(5):685–
90  
Yu H-S, Lin T-H, Tang C-H. Involvement of Intercellular Adhesion Molecule-1 Up-
Regulation in Bradykinin Promotes Cell Motility in Human Prostate Cancers. Int. J. Mol. 
Sci. Multidisciplinary Digital Publishing Institute; 2013;14(7):13329–45  
Zhou L, Wang L, Lu L, Jiang P, Sun H, Wang H. Inhibition of miR-29 by TGF-beta-
Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse 
90 
 
myoblasts into myofibroblasts. PLoS One. 2012;7(3):e33766  
 
 
